### nature aging

Article

https://doi.org/10.1038/s43587-024-00575-6

# Plasma membrane damage limits replicative lifespan in yeast and induces premature senescence in human fibroblasts

Received: 25 July 2022

Accepted: 26 January 2024

Published online: 22 February 2024

Check for updates

Kojiro Suda<sup>1,7</sup>, Yohsuke Moriyama<sup>1,7</sup>, Nurhanani Razali<sup>1,7</sup>, Yatzu Chiu<sup>1</sup>, Yumiko Masukagami<sup>1</sup>, Koutarou Nishimura<sup>2</sup>, Hunter Barbee<sup>1</sup>, Hiroshi Takase<sup>3</sup>, Shinju Sugiyama<sup>1</sup>, Yuta Yamazaki<sup>1</sup>, Yoshikatsu Sato<sup>4</sup>, Tetsuya Higashiyama<sup>4,5</sup>, Yoshikazu Johmura<sup>6</sup>, Makoto Nakanishi<sup>6</sup> Keiko Kono<sup>1</sup>

Plasma membrane damage (PMD) occurs in all cell types due to environmental perturbation and cell-autonomous activities. However, cellular outcomes of PMD remain largely unknown except for recovery or death. In this study, using budding yeast and normal human fibroblasts, we found that cellular senescence—stable cell cycle arrest contributing to organismal aging— is the long-term outcome of PMD. Our genetic screening using budding yeast unexpectedly identified a close genetic association between PMD response and replicative lifespan regulations. Furthermore, PMD limits replicative lifespan in budding yeast; upregulation of membrane repair factors ESCRT-III (*SNF7*) and AAA-ATPase (*VPS4*) extends it. In normal human fibroblasts, PMD induces premature senescence via the Ca<sup>2+</sup>–p53 axis but not the major senescence pathway, DNA damage response pathway. Transient upregulation of ESCRT-III (CHMP4B) suppressed PMD-dependent senescence. Together with mRNA sequencing results, our study highlights an underappreciated but ubiquitous senescent cell subtype: PMD-dependent senescent cells.

Cells experience a variety of perturbations on the plasma membrane, ranging from physical attack to pathogen invasion<sup>1</sup>. The plasma membrane is also damaged by physiological activities, including muscle contraction<sup>1-3</sup>. There is a growing appreciation that failed plasma membrane damage (PMD) response causes various diseases. For example, mutations in the PMD repair protein dysferlin can lead to one form of muscular dystrophy<sup>4</sup>, and mutations in the PMD response factor lipid scramblase TMEM16F cause Scott syndrome<sup>5,6</sup>.

The PMD response is classified into two simple outcomes of recovery or death. Regarding the recovery response, plasma membrane repair mechanisms, including Ca<sup>2+</sup>-dependent lysosomal fusion to the plasma membrane and the endosomal sorting complexes required for transport (ESCRT) complex-dependent membrane scission, have been extensively studied in multiple eukaryotic systems<sup>1-4,7-11</sup>. In contrast, the PMD-induced cell death response, pyroptosis, has been studied mostly in mammalian cells and in the context of the immune response or cancer treatment<sup>12,13</sup>. Although these studies revealed the molecular mechanisms underlying the survival or death response after PMD in each system, a unified view of PMD response in eukaryotes remains largely elusive, partly because of the lack of a universal PMD induction method. In particular, the PMD-inducing chemicals used in mammalian cells, such as streptolysin O (SLO) or

<sup>1</sup>Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan. <sup>2</sup>Department of Hematology-Oncology, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Hyogo, Japan. <sup>3</sup>Core Laboratory, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan. <sup>4</sup>Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Nagoya, Japan. <sup>5</sup>Department of Biological Science, Graduate School of Science, University of Tokyo, Tokyo, Japan. <sup>6</sup>Division of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. <sup>7</sup>These authors contributed equally: Kojiro Suda, Yohsuke Moriyama, Nurhanani Razali. e-mail: keiko.kono@oist.jp



Fig. 1 | SDS induces PMD in yeast and human cells. a, Wild-type yeast cells were cultured in YPD and then incubated with 2 ng ml<sup>-1</sup> DAPI-containing YPD with or without 20 mM EGTA and 0.02% SDS for 15 min. Scale bar, 5 µm. b, Quantification of a. Data are presented as mean (horizontal bars) ± s.d. (whiskers) of three independent experiments (n > 300 cells per each experiment). \*\*\*\*P < 0.001: control versus EGTA+SDS: <0.0001; EGTA versus EGTA+SDS: <0.0001; EGTA versus EGTA+SDS: <0.0001, by two-tailed unpaired Student's t-test. c, Wildtype yeast cells were cultured at 25 °C and then incubated with 0.02% SDS for 2 h. Cells were fixed and observed by TEM. Yellow arrows, plasma membrane and cell wall ingression. Scale bar, 1 µm. d, Wild-type yeast cells were cultured in YPD and then switched to YPD containing 0.02% SDS for 3 h. Yeast cells were treated with zymolyase in 1.2 M sorbitol for 90 min and then stained with Annexin V-Alexa Fluor 568 for 20 min. Yellow arrows, Annexin V and Calcofluor white positive spots. e, The percentage of cells with Annexin V staining outside of the bud scar was counted. Data are presented as mean (horizontal bars) ± s.e.m. (whiskers) of three independent experiments. n > 250 cells per each experiment.

perforin, cannot be easily adopted to cell types with a rigid cell wall, including yeast.

Yeast serves as an excellent genetic tool to comprehensively identify genes required for fundamental cellular processes in eukaryotes. Previously, we demonstrated that budding yeast is equipped with a mechanism for repairing laser-induced PMD<sup>14,15</sup>. Although laser damage is a universal PMD method applicable for both budding yeast and higher eukaryotes, it cannot be easily employed in large-scale analysis. 2 µm. **f**, Representative images of HeLa cells with DAPI signals upon 0.008% SDS treatment for 24 h. The cells were cultured in a DAPI-containing medium with or without 0.008% SDS. Scale bar, 20 µm. **g**, Quantification of DAPI intensity as in **f**. Data are presented as mean (horizontal bars)  $\pm$  s.d. (whiskers) of three independent experiments. Untreated control and 0.008% SDS treatment were significantly different (\*\*P < 0.01, exact value: 0.0086) using two-sided multiple Welch's *t*-test with Benjamini, Krieger and Yekutieli correction. See also Extended Data Fig. 2. **h**, Representative images of the HeLa cells with Annexin V–positive spots/blebs upon 0.008% SDS treatment. Cells were cultured in a medium with or without 0.008% SDS for 1 h. Scale bar, 20 µm. BF, bright-field. **i**, Numbers of Annexin V–positive spots/blebs were counted as in **h**. Data are presented as mean (horizontal bars)  $\pm$  s.d. (whiskers) of three independent experiments (black dots). See also Extended Data Fig. 3a. \*\*P < 0.01, exact value: 0.000292, by two-tailed unpaired Student's *t*-test.

\*\*P<0.01, exact value: 0.005, by two-tailed unpaired Student's t-test. Scale bar,

In the present study, we developed a simple PMD induction method that can be used both in budding yeast and human cultured cells. Using the assay, we performed the genome-wide screening using yeast and found that PMD limits replicative lifespan in budding yeast and induces premature senescence in normal human fibroblasts. Although cellular senescence is induced by various triggers, including DNA damage, telomere shortening and oncogene activation, little was known about PMD-dependent senescence (PMD-Sen). Time-resolved mRNA sequencing (mRNA-seq) results indicate that PMD-dependent senescent cells (PMD-Sen cells) have different gene expression profiles, including the upregulation of wound healing genes. PMD-Sen may explain the origin of senescent cells around cutaneous wounds in vivo<sup>16</sup>.

#### Results

#### A simple and universal plasma membrane damaging method

To reveal the conserved features of the PMD response in eukaryotes, we needed a simple and reliable PMD-inducing method that can be (1) applicable for both budding yeast and human cells and (2) used in large-scale analyses. A candidate chemical was sodium dodecyl sulfate (SDS) because, previously, we showed that wild-type budding yeast cells can grow on a yeast extract peptone dextrose (YPD) plate containing 0.02% SDS, but yeast mutants that are defective in the PMD response fail to grow on it<sup>14,15</sup>. We tested whether SDS breaks cell wall and plasma membrane, which would lead to the penetration of a scarcely membrane-permeable fluorescent chemical, 4',6-diamidino-2-phenylindole (DAPI). DAPI goes into only  $9.8 \pm 3.9\%$  of wild-type budding yeast cells, consistent with the fact that wild-type budding yeast can reseal the wound immediately and survive in the presence of SDS. However, in combination with ethyl glycol tetraacetic acid (EGTA), which prevents  $Ca^{2+}$ -dependent membrane resealing<sup>9</sup>, DAPI penetrated 74.5 ± 4.9% of cells (Fig. 1a,b). These results suggest that SDS breaks the plasma membrane, and the damage is immediately resealed by Ca<sup>2+</sup>-dependent mechanisms.

To investigate whether SDS also damages the cell wall, we observed chitin that staunches the laser-induced cell wall damage<sup>15</sup>. We found local chitin spots in 84.9  $\pm$  5.5% of cells after SDS treatment (Extended Data Fig. 1a, white arrows), analogous to the phenotype after laser damage (Extended Data Fig. 1b, yellow arrows). Consistently, transmission electron microscopy (TEM) images showed that SDS treatment induced local ingression of the cell wall and plasma membrane structure (Fig. 1c, yellow arrows). These results suggest that SDS breaks both cell wall and plasma membrane and that the damage is local, forming individual spots.

Next, phosphatidylserine (PS) externalization was examined because plasma membrane damage leads to local PS externalization in human cells<sup>17</sup>. Unexpectedly, PS was externalized at the bud scars, former cytokinesis sites marked by circular chitin staining in budding yeast, before the SDS treatment (Fig. 1d, upper panels). In addition to the signal at the bud scars, PS-externalized spots increased after SDS treatment, and the PS spots co-localized with chitin spots (Fig. 1d, lower panels, and Fig. 1e). Moreover, two major repair proteins, Pkc1-GFP and Myo2-GFP, were recruited locally, but not globally, to the cortex after SDS treatment (Extended Data Fig. 1c, yellow arrows). Together, these results demonstrate that SDS induces local plasma membrane and cell wall damage in budding yeast.

To test whether SDS damages the plasma membrane of human cultured cells, we performed the membrane-impermeable fluorescent dye penetration assay. We found that SDS treatment induced the influx of DAPI and FM1-43 into HeLa cells (Fig. 1f,g and Extended Data Fig. 2a–e). In addition, the PS-externalized spots/blebs at the cell periphery increased after SDS treatment in HeLa cells (Fig. 1h,i and Extended Data Fig. 3a,b), analogous to the treatment with other

Fig. 2 | Identification of genes required for PMD response in budding yeast; PMD limits replicative lifespan in budding yeast. a, The genes required for the growth in the presence of 0.02% SDS. b, ESCRT mutants were spotted on YPD plates (4× dilution series) with or without 0.02% SDS, incubated at 25 °C for 3 d. c, Enriched GO terms. See also Supplementary Table 1. d, Fold enrichment scores in the GO enrichment analysis were plotted. e, Wild-type,  $snf7\Delta$ ,  $vps34\Delta$ and  $erg2\Delta$  were subjected to the replicative lifespan measurement. Median values are shown. Cell number: wild-type (n = 24),  $vps34\Delta$  (n = 24),  $snf7\Delta$  (n = 24) and  $erg2\Delta$  (n = 25). f, Wild-type, VPS4-overexpressing or SNF7-overexpressing yeast cells were subjected to the replicative lifespan measurement. Median values are membrane-poring reagents<sup>17</sup>. Live cell imaging confirmed that PSexternalized spots/blebs increased after SDS treatment in WI-38 cells (Extended Data Fig. 3c). Plasma membrane repair protein ESCRT-III (CHMP4A) signals were detected at the PS-externalized spots/blebs (Extended Data Fig. 3d). These results indicate that SDS treatment induces PMD in human cells. Using this simple treatment, we designed a genome-wide screen to identify factors required for plasma membrane repair in budding yeast.

#### Identification of the PMD response genes in budding yeast

To identify genes essential for the PMD responses, we performed a genome-wide screen using two yeast libraries—non-essential gene deletion library<sup>18</sup> and DAmP library—in which mRNA levels of essential genes are decreased to 20–50% (ref. 19). These two libraries account for 96% of all open reading frames in budding yeast. We identified 48 mutants that were reproducibly sensitive to SDS (Fig. 2a and Supplementary Fig. 1a,b). The screening hits could be manually classified into 19 functional groups. The largest group in the hits was ESCRT with eight genes (Fig. 2b). Gene Ontology (GO) enrichment analysis (http://geneontology.org) revealed that the cellular processes associated with ESCRT were highly enriched (Fig. 2c,d and Supplementary Table 1). Thus, ESCRT's cellular function is essential for the PMD response in budding yeast, analogous to what was previously shown in higher eukaryotes<sup>1-4,7-11</sup>.

We performed characterization of the screening hits (Extended Data Fig. 4a–k and Supplementary Fig. 2). The details are explained in the Supplementary Text. In short, ESCRT mutants ( $did4\Delta$ ,  $snf7\Delta$ ,  $stp22\Delta$ ,  $vps20\Delta$ ,  $vps25\Delta$ ,  $vps36\Delta$  and  $vps24\Delta$ ) survived for at least 2 h in the SDS-containing medium. In contrast, V-ATPase mutants ( $vma21\Delta$ ,  $vph2\Delta$ ,  $vma5\Delta$ ,  $vma1\Delta$  and  $vma13\Delta$ ) lost their viability after 30-min incubation in the medium containing SDS (Extended Data Fig. 4a–d). V-ATPase produces a proton gradient across the vacuolar membrane, enabling Ca<sup>2+</sup> uptake into the vacuole; the mutants lacking functional V-ATPase show high cytoplasmic Ca<sup>2+</sup> levels. Because Ca<sup>2+</sup> influx at the damage site is essential for membrane resealing in higher eukary-otes<sup>6,7</sup>, SDS sensitivity in V-ATPase mutants may be explained by the high cytosolic Ca<sup>2+</sup> concentration in V-ATPase mutants, preventing membrane resealing.

Together with further characterization described in the Supplementary Text, here we reveal four cellular processes during plasma membrane/cell wall damage response in budding yeast: (1) V-ATPasedependent prevention of immediate cell death, (2) Crz1 nuclear import, (3) PS recruitment to the damage site and (4) Pep3-dependent and Vps34dependent retention of Pkc1 at the damage site (Supplementary Fig. 2).

#### PMD limits the replicative lifespan of budding yeast

The gene sets required for the cellular/subcellular processes after plasma membrane damage should be enriched in our hits. To identify the reported phenotype enriched for our hits, we performed model organism Phenotype Enrichment Analysis (*mod*PhEA)<sup>20</sup> (http://evol. nhri.org.tw/phenome2). We found that the genes associated with the phenotype 'replicative lifespan' were significantly enriched (Supplementary Tables 2 and 3). Motivated by this finding, we performed a replicative lifespan analysis<sup>21</sup> using our screening hits. All three mutants tested (*snf7* $\Delta$ , *vps34* $\Delta$  and *erg2* $\Delta$ ) showed no growth in the presence of

shown. Cell number: wild-type (n = 48), VPS4 (n = 48), SNF7 (n = 48). **g**, Wild-type, VPS4-overexpressing or SNF7-overexpressing yeast cells were subjected to the replicative lifespan measurement with or without 0.02% SDS. Median values are shown. Cell number: wild-type (n = 24), SDS (n = 24), SDS+VPS4 (n = 24) and SDS+SNF7 (n = 25). \*P < 0.05, \*\*P < 0.01 and \*\*\*\*P < 0.001, by two-sided Wilcoxon rank-sum test. Exact *P* value: wild-type versus *vps34* $\Delta$ : <0.0001, wild-type versus *snf7* $\Delta$ : <0.0001 and wild-type versus *erg2* $\Delta$ : 0.0029 (**e**); wild-type versus *VPS4*: 0.0087 and wild-type versus SNF7: 0.0116 (**f**); wild-type versus SDS+SNF7: 0.0394 (**g**). In **e**-**g**, the median lifespan is indicated as a gray horizontal line. WT, wild-type.

#### Article

а

SDS, which is consistent with our screening strategy (Supplementary Fig. 1).  $snf7\Delta$ ,  $vps34\Delta$  and  $erg2\Delta$  cells showed markedly shorter replicative lifespan, in the absence of SDS, compared to wild-type cells (Fig. 2e and Extended Data Fig. 5a), further suggesting a link between the PMD responses and replicative lifespan regulation. Consistent with these results, overexpression of the ESCRT activator AAA-ATPase VPS4 and overexpression of ESCRT-III SNF7 extended the replicative lifespan (Fig. 2f and Extended Data Fig. 5b). Next, we examined the replicative lifespan of wild-type cells, VPS4-overexpressing cells and SNF7-overexpressing cells in the presence or absence of SDS. We found that SDS significantly shortened the replicative lifespan of wild-type yeast cells and that overexpression of VPS4/SNF7 partially suppressed it (Fig. 2g and Extended Data Fig. 5c). To test whether the mechanical injury shortens yeast replicative lifespan, we introduced a mechanical

Gene	Systematic name	Function	
DID4	YKLOO2W	_	
SNF7	YLR025W		
STP22	YCL008C	_	
VPS20 YMR077C		ESCRT	
VPS24	YKLO41W		
VPS25	YJR102C		
VPS36	YLR417W		
VPS4	YPR173C		
VMA1	YDL185W		
VMA13	YPR036W		
VMA21	YGR105W		
VMA5	YKL080W	V-All ase	
VMA9	YCL005W-A		
VPH2	YKL119C		
AAT2	YLR027C		
ARO1	YDR127W		
ARO2	YGL148W	Amine and bicounthesis (compared to be light	
ARO7	YPR060C	Amino acid biosynthesis/sensor/metabolism	
TRP4	YDR354W		
TRP5	YGL026C		
DEF1	YKL054C		
FYV6	YNL133C		
RFA2 YNL312W		DNA replication/damage/repair	
SEN1	YLR430W		
ACB1	YGR037C		
CHO1	YER026C	-	
ERG2	YMR202W	Lipid	
ERG3	YI R056W	-	
RPB3	YII 021W		
PRP22	VER013W	RNA helicase/polymerase	
PRP43	YGI 120C		
ISA1	YI I 027W		
ISA2	VPR067W	Mitochondria	
MRPI 51	VPR100w		
VPS16			
PEP?	VI P1/8W	SNARE/HOPS	
	VI 02260		
	1LK3300	Ribosome	
DUODE	10K398W		
PHU85	YPL03TC		
GASI			
SIHI	YIL126W	Unromatin remodeling	
SWA2	YDR320C	Endocytosis/exocytosis	
VPS34	YLR240W	PI3-kinase	
IPD3	YAL016W	PP2A	
PIC1	YDL006W	PP2C	
ARF1	YDL192W	Ras GTPase	
CCR4	YAL021C	Transcription	
KCS1	YDR017C	Inositol/vacuole	

100

75

50

25

0

0

5 10

Cell viability (%)





Enrichment

WT (23.0)

15 20 25 30 35 40

Number of divisions

0

GO term
Intralumenal vesicle formation (GO:0070676)
Chorismate metabolic process (GO:0046417)
ATP export (GO:1904669)
Endosome organization (GO:0007032)
Aromatic amino acid family biosynthetic process (GO:0009073)
Reticulophagy (GO:0061709)
Protein retention in Golgi apparatus (GO:0045053)
Vesicle budding from membrane (GO:0006900)
Vacuolar acidification (GO:0007035)
Intracellular pH reduction (GO:0051452)
pH reduction (GO:0045851)







Number of divisions

100

75

50

25

0

0

5 10 15 20 25 30 35 40 45

Cell viability (%)

WT (22.0)

vps34∆ (14.0)\*\*\*\*

snf7∆ (8.0)\*\*\*\*

erg2∆ (17.0)\*\*

stress, where yeast cells were smashed between a glass needle and a glass coverslip. We found that this treatment also shortened the replicative lifespan of wild-type cells (Extended Data Fig. 5d–f). These results suggest that PMD limits the replicative lifespan of budding yeast and that ESCRT's function is critical for the regulation of replicative lifespan.

# Transient PMD induces senescence in normal human fibroblasts

To test the possibility that PMD induces premature senescence in human cells, we performed a long-term culture of normal human fibroblasts (WI-38, HCA2 and BJ) in the presence or absence of PMD. Indeed, cell proliferation was inhibited in an SDS concentrationdependent manner (Fig. 3a, Extended Data Fig. 6a, b and Supplementary Fig. 3).

To minimize side effects, we transiently treated normal human fibroblasts with SDS. WI-38 and HCA2 cells were incubated with SDS-containing media for 24 h, washed with medium and then cultured in fresh medium. We found that cell proliferation was inhibited after the treatment, and the proportion of senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal)-positive cells was increased after 10 d (Fig. 3b,c and Extended Data Fig. 6c,d). 5-Ethynyl-2'-deoxyuridine (EdU) incorporation was attenuated in the cells 16 d after the PMD treatment, indicating that DNA replication halted (Fig. 3d). Consistently, the protein levels of p53 (Fig. 3e and Extended Data Fig. 6e), an essential senescence regulator in mammalian cells<sup>22,23</sup>, and its target, p21, increased in cells treated with SDS as early as 24 h after SDS wash away (Fig. 3e and Extended Data Fig. 6e). p53 is known to be phosphorylated at multiple sites by several different kinases. For example, DNA damage response induces p53 phosphorylation at Ser15 (refs. 24-26), and osmotic shock or UV irradiation (IR) induces p53 phosphorylation at Ser33 (refs. 27,28). Notably, p53 phosphorylation at Ser33, but not Ser15, increased 24 h after SDS treatment (Fig. 3e). We found that the levels of p16 also increased 48 h after the SDS wash away (Fig. 3e and Extended Data Fig. 6f). The mRNA levels of senescence-associated secretory phenotype (SASP) factors IL6 and CCL2 were upregulated in SDS-treated cells, analogous to replicative senescent and DNA damage-treated cells (Fig. 3f). Together, these results suggest that PMD induced by SDS promotes cellular senescence in normal human fibroblasts.

To generalize our finding, we tested other plasma membranedamaging stimuli, including SLO, silica and laser damage. Penetration assay using a barely membrane-permeable dye, propidium iodide (PI), confirmed successful PMD induction after SLO treatment and silica treatment (Extended Data Fig. 6g). Consistently, SLO treatment and silica treatment induced senescent cell features, including

#### Fig. 3 | Transient PMD induces premature senescence in normal human

fibroblasts. a, PDLs of WI-38 cells. WI-38 cells were cultured continuously in the medium containing SDS (0.005-0.009%, indicated on the right). b-f, WI-38 cells were incubated with 0.007% SDS or 250 nM DXR for 24 h, washed and released into fresh medium. **b**, Relative cell numbers are indicated. **c**, SA-β-gal-positive cells were detected using the cells 10 d after wash away. Scale bar, 200 µm. n > 100 cells.\*\*\*\*P < 0.001: control (Ctl) versus SDS: <0.0001 and Ctl versus DXR: <0.0001, by one-way ANOVA with Dunnett' s test. d, WI-38 young cells (Ctl) and senescent cells (SDS, DXR and RS) were labeled with 10 µM EdU for 24 h. EdU-Alexa Fluor 647 signals and Hoechst 33342 signals were obtained, and the ratio of EdU-incorporated cells was calculated. n > 200 cells. \*\*\*\*P < 0.001: Ctl versus SDS: <0.0001; Ctl versus DXR: <0.0001; Ctl versus RS: <0.0001, by one-way ANOVA with Dunnett's test. e, Western blotting using the cell lysates of WI-38 cells treated with SDS or DXR. The cells after 24-h treatment were collected at the indicated times after wash away. f, qPCR analysis of SASP genes (IL6 and CCL2) in senescent WI-38 cells. RNA was isolated from WI-38 untreated cells (Ctl), 5 d after SDS or DXR wash away and RS. \*P<0.05, \*\*P<0.01 and \*\*\*P<0.001, by oneway ANOVA with Dunnett's test. Exact P value: IL6\_Control versus SDS: 0.0045,

proliferation arrest, increase in the proportion of SA- $\beta$ -gal-positive cells and upregulation of p53, p21 and p16 protein levels as well as the SASP factors *IL6* and *CCL2* mRNA levels (Fig. 3g–j). Similar to SDS-dependent PMD, p53 phosphorylation at Ser33, but not at Ser15, was increased 24 h after SLO and silica treatment. Moreover, laser damage at the plasma membrane also induced senescent cell features, including proliferation arrest, enlarged cell morphology and increase in the proportion of SA- $\beta$ -gal-positive cells (Extended Data Fig. 6h,i). After the laser damage, the cells did not show detectable DNA damage marked with  $\gamma$ H2AX immunostaining (Extended Data Fig. 6j). Together, these results suggest that PMD triggers premature senescence in normal human fibroblasts.

#### PMD-dependent senescence is suppressed by CHMP4B

To test whether upregulation of plasma membrane repair suppresses PMD-Sen, we examined whether transient overexpression of ESCRT-III (CHMP4B) suppresses PMD-Sen. We transfected the plasmid harboring GFP-CHMP4B into WI-38 cells, and the cells were treated with SDS as described above. We found that overexpression of CHMP4B, only transient overexpression during the SDS treatment, bypassed SDS-induced proliferation arrest and decreased the proportion of SA- $\beta$ -galpositive cells (Fig. 4a,b). Consistent with these results, SDS-induced upregulation of p53, p21 and p16 protein levels was attenuated in the CHMP4B-expressing cells (Fig. 4c). SASP factor upregulation was suppressed as well (Fig. 4d). Together, these results are consistent with our understanding that PMD induces cellular senescence and that upregulation of plasma membrane repair suppresses it.

#### PMD induces senescence via p53 in normal human fibroblasts

The best-characterized cellular senescence mechanism is the DNA damage response pathway-dependent upregulation of p53-p21, which is activated after many senescence-inducing stimuli, including telomere shortening, DNA damage and oncogene activation<sup>29,30</sup>. We tested whether this pathway is activated after PMD. SDS treatment increased the protein levels of p53 and p21. However, the DNA damage markers yH2AX and phospho-ATM did not increase at least up to 48 h after SDS wash away (Fig. 3e and Extended Data Fig. 6e). Consistent with these results, yH2AX signal was undetectable in the cells at 24 h after the SDS wash away (Fig. 5a and Extended Data Fig. 7a). These results suggest that the DNA damage response pathway is dispensable for PMD-dependent upregulation of p53-p21.

To test this possibility further, WI-38 and HCA2 cells were treated with the inhibitors of ATM and DNA-PKs (Fig. 5b,c and Extended Data Fig. 7b,c). Both inhibitors did not alter the SDS-dependent upregulation of p53 and p21. In contrast, p53 knockdown abolished p21 induction (Fig. 5d and Extended Data Fig. 7d) and significantly decreased the

IL6 Control versus DXR: 0.0309, IL6 Control versus RS: 0.0002, CCL2 Control versus SDS: 0.0318, CCL2 Control versus DXR: 0.033, CCL2 Control versus RS: <0.0001. g-j, WI-38 cells were incubated with 200 ng ml<sup>-1</sup> SLO, 125 µg ml<sup>-1</sup> silica (diameter, 0.8  $\mu$ m) (Silica) or 250 nM DXR for 24 h, washed and released into fresh medium. **g**, Cell number was counted 10 d after wash away. \*\*\*\*P < 0.001: Ctl versus SLO: <0.0001 and Ctl versus Silica: <0.0001, by one-way ANOVA with Dunnett' s test. **h**, SA- $\beta$ -gal-positive cells were detected 10 d after wash away. Scale bar, 50  $\mu$ m. Graphs show quantification of SA- $\beta$ -gal-positive cells (n > 100cells). \*\*P < 0.01 and \*\*\*P < 0.005: Ctl versus SLO: 0.0022 and Ctl versus Silica: 0.0009, by one-way ANOVA with Dunnett's test. i, Western blotting using the cell lysates of WI-38 cells treated with SLO or Silica for 24 h. Cells were collected at the indicated times after wash away. j, qPCR analysis of *IL6* and *CCL2* gene expression. RNA was isolated 5 d after wash away. \*P < 0.05, \*\*P < 0.01 and \*\*\*P < 0.001, by one-way ANOVA with Dunnett' s test. Exact P value: IL6\_Control versus SLO: 0.0012, IL6\_Control versus Silica: 0.0001, CCL2\_Control versus SLO: 0.0179 and CCL2\_Control versus Silica: 0.0031. Data in c, d and f-j are presented as mean  $(horizontal bars) \pm s.d.$  (whiskers) of at least three biological replicates.

proportion of SA-β-gal-positive cells after SDS wash away (Fig. 5e and Extended Data Fig. 7e). p16 level was increased by p53 knockdown, as previously described<sup>31</sup>. Complementarily, DNA damage-inducing doxo-rubicin (DXR) treatment did not induce detectable plasma membrane rupture in the DAPI penetration assay (Extended Data Fig. 7f,g). Considering these results, we conclude that PMD induces cellular senescence via p53; however, the upregulation of p53 is regulated by a mechanism independent of the best-characterized senescence pathway: the DNA damage response pathway.

#### Ca<sup>2+</sup> influx mediates PMD-dependent senescence

 $Ca^{2+}$  influx is one of the earliest responses after PMD in all cell types<sup>1,2</sup>, and  $Ca^{2+}$  signaling is involved in cellular senescence<sup>32</sup>. To test whether  $Ca^{2+}$  influx mediates cellular senescence after PMD, first, we tested cytosolic  $Ca^{2+}$  levels after SDS treatment. We found that cytosolic  $Ca^{2+}$  levels increased at 1 min after the SDS addition (Extended Data Fig. 8a–c). Next, we examined whether BAPTA-AM, cell-permeable cytosolic  $Ca^{2+}$  chelator, suppresses PMD-Sen. We administered BAPTA-AM in combination with SDS treatment and found that BAPTA-AM markedly





Fig. 4 | Transient overexpression of ESCRT-III (CHMP4B) suppressed PMDdependent senescence. a–d, A control plasmid (GFP) or a plasmid encoding ESCRT-III (GFP-CHMP4B) was overexpressed in WI-38 cells. The cells were treated with 0.007% SDS for 24 h, washed and released into fresh medium. a, Cell number in a 6-cm-diameter dish was counted 10 d after SDS wash away. \*P < 0.05, exact value: 0.0468, by two-tailed unpaired Student's *t*-test. b, SA- $\beta$ -gal-positive cells were detected 7 d after SDS wash away. Scale bar, 50 µm. Graphs show quantification of SA- $\beta$ -gal-positive cells (n > 100 cells). \*P < 0.01, exact value: 0.0067, by two-tailed unpaired Student's *t*-test. c, Western blotting using the cell lysates of WI-38 cells treated with SDS for 24 h that were collected at the indicated times after wash away. GFP (control) and GFP-CHMP4B expression was confirmed by anti-GFP blot. Relative signal intensities are quantified. \*P < 0.05, by one-way ANOVA with Dunnett's test. Exact *P* value: p53\_Ctl versus 96 h in control (Ctl) cells: 0.0491; p53\_Ctl versus 96 h in CHMP4B-expressed cells: 0.4648; p21\_ Ctl versus 96 h in Ctl cells: 0.0477; p21\_Ctl versus 96 h in CHMP4B-expressed cells: 0.5864; p16\_Ctl versus 96 h in Ctl cells: 0.0195; p16\_Ctl versus 96 h in CHMP4Bexpressed cells: 0.5793. **d**, qPCR analysis of *IL6* and *CCL2* gene expressions. RNA was isolated 5 d after wash away. \*\*\**P* < 0.005 and \*\*\*\**P* < 0.001, by one-way ANOVA with Dunnett's test. Exact *P* value: *IL6*\_Ctl versus SDS in Ctl cells: <0.0001; *IL6*\_Ctl versus SDS in CHMP4B-expressed cells: 0.1843; *CCL2*\_Ctl versus SDS in Ctl cells: <0.0009; *CCL2*\_Ctl versus SDS in CHMP4B-expressed cells: 0.2306. Data in **a**-**d** are presented as mean (horizontal bars) ± s.d. (whiskers) of three biological replicates. NS, not significant.

suppressed senescent cell features, including SDS-induced proliferation arrest, SA- $\beta$ -gal positivity, p53–p21 upregulation and *IL6* mRNA upregulation (Fig. 6a–d). Intriguingly, SDS-dependent upregulation of p16 and *CCL2* were not suppressed by BAPTA-AM (Fig. 6c,d). These results suggest that PMD-Sen is regulated by at least two pathways: Ca<sup>2+</sup> influx-dependent and influx-independent pathways. In line with these results, enforced plasma membrane Ca<sup>2+</sup> channel opening and Ca<sup>2+</sup> influx by KCl for 24 h was sufficient for increasing the proportion of SA- $\beta$ -gal-positive cells after KCl wash away (Fig. 6e). The levels of senescent marker proteins p53, p21 and p16 also increased after KCl wash away (Fig. 6f). These results are consistent with our idea that Ca<sup>2+</sup> influx is required and sufficient for p53 induction during PMD-Sen (Fig. 6g).

#### The specific mRNA expression transition in PMD-Sen

To understand the dynamics of gene expression profile changes during PMD-Sen, we performed mRNA-seq using the WI-38 cells collected at each timepoint during senescence progression (day 0 to day 16; day 0 corresponds to the day of the SDS wash away; Extended Data Fig. 8d–g) and compared the result with other senescence subtypes—that is, DNA damage response-dependent senescence (DDR-Sen) by DXR treatment,



Fig. 5| PMD-dependent senescence requires p53. a-e, WI-38 cells were treated with 0.007% SDS or 250 nM DXR combined with indicated additional treatment for 24 h, washed and released into fresh medium. a,  $\gamma$ H2AX staining. WI-38 cells at 24 h after SDS or DXR wash away and untreated cells (control) were stained with  $\gamma$ H2AX (red) and with DAPI (blue). Scale bar, 50  $\mu$ m. Graphs show quantification of  $\gamma$ H2AX-positive cells (*n* > 100 cells). \*\*\*\**P* < 0.001, control versus SDS: 0.9896 and control versus DXR: <0.0001, by one-way ANOVA with Dunnett' s test. b-d, Western blotting using cell lysates of WI-38 cells treated with SDS with or without ATM inhibitor KU-55944 (10  $\mu$ M) (b), DNA-PK inhibitor (10  $\mu$ M) (c) and p53 siRNA (d). e, SA- $\beta$ -gal-positive cells were counted on 10 d after wash away. WI-38 cells were treated with p53 siRNA (sip53) or control scramble siRNA (siControl). \*\**P* < 0.01, exact value: 0.0091, by two-tailed unpaired Student's *t*-test. Data in a and e are presented as mean (horizontal bars) ± s.d. (whiskers) of three biological replicates. NS, not significant.

Ca<sup>2+</sup>-dependent senescence (Ca<sup>2+</sup>-Sen) by KCl treatment and replicative senescence (RS) by repeated passaging. We analyzed the mRNA-seq results using Ingenuity Pathway Analysis (IPA) software, which allows us to use manually curated cell-type-specific databases, enabling reliable prediction of the functions of pathways and genes. First, we identified the pathways significantly activated/inhibited during PMD-Sen, in comparison with DDR-Sen, Ca<sup>2+</sup>-Sen and RS (Supplementary Fig. 4). The enrichment of the top canonical pathways was examined using Fisher's exact test. This analysis successfully identified 21 top canonical pathways that are activated/inhibited during PMD-Sen whose activation *z*-score values are greater than 2 (activation) or smaller than -2 (inhibition). IPA's *z*-score indicates a predicted activation or inhibition of a pathway/gene, where a positive *z*-value connotates an overall pathway's activation and a negative *z*-value connotates an overall pathway's inhibition.

According to the same cutoff *z*-score values, we also identified 21 top canonical pathways in Ca<sup>2+</sup>-Sen and DDR-Sen. Ten out of 21 pathways were common among PMD-Sen, DDR-Sen and Ca<sup>2+</sup>-Sen (Supplementary Fig. 4, gray boxes, and the bottom-left table). The common features of PMD-Sen, Ca<sup>2+</sup>-Sen and DDR-Sen are the inhibition of cell-cycle-related pathways and the activation of the senescence pathway (Fig. 7a and Supplementary Fig. 4). Although the senescence pathway was activated in all senescence subtypes examined here, we noticed that the kinetics of activation was different. In PMD-Sen, the senescence pathway was activated only on day 3 and later (Fig. 7a). In contrast, the senescence pathway was steadily upregulated in DDR-Sen. These results suggest that the progression of senescence is slower in PMD-Sen than in DDR-Sen.

# Glycoprotein VI signaling pathway inhibition is associated with SASP

Although the inhibition of cell-cycle-related pathways and the activation of the senescence pathway are the common features of all senescent cell subtypes, there are pathways differentially regulated among different senescent cell subtypes. The IPA pathway comparison analyses identified glycoprotein VI (GPVI) signaling pathway that was strongly inhibited in early PMD-Sen and Ca<sup>2+</sup>-Sen but not in DDR-Sen (Fig. 7a and Supplementary Fig. 4). These results raise a possibility that GPVI signaling pathway inhibition is downstream of Ca<sup>2+</sup> influx because Ca<sup>2+</sup> influx is one of the earliest common cellular processes after SDS treatment and KCI treatment.

Next, we extracted the SASP factors, based on the SASP Atlas<sup>33</sup>, from the differentially expressed genes identified in our mRNA-seq (Supplementary Table 4). Using these SASP factors, we performed IPA pathway analysis and found that the GPVI signaling pathway was strongly inhibited in early PMD-Sen (Fig. 7b and Supplementary Fig. 5). These results suggest that the downregulation of GPVI signaling pathway is closely associated with the SASP factors.

#### Potential link between wound healing and PMD-Sen

In the IPA pathway analysis of SASP factors differentially expressed in senescent cells, the transient upregulation of wound healing SASP factors was observed in PMD-Sen (Fig. 7b and Supplementary Fig. 5). Therefore, we speculated that plasma membrane damage could be the in vivo trigger of the senescent cell accumulation around the tissue injury sites. To explore this possibility, we compared a publicly available mRNA-seq dataset derived from cutaneous wound cells<sup>34</sup> with our mRNA-seq results. Strikingly, we found that the pathways that were significantly changed in cutaneous wound cells substantially overlapped with PMD-Sen cells, particularly on day 0 or day 16 (Fig. 7c, Extended Data Fig. 9a, b and Supplementary Tables 5 and 6). To exclude the possibility that this tendency is an artifact due to fewer number of pathways identified in DDR-Sen, we used the same number of pathways (top 146 pathways) for all datasets, regardless of the z-score cutoff line (Extended Data Fig. 9b and Supplementary Table 6). We verified that the result was consistent with the earlier analyses.

To investigate whether PMD-Sen cells have functions associated with wound healing in vitro, we examined whether PMD-Sen cells alter the migration rate of young normal fibroblast cells in a paracrine manner. Indeed, the migration assays in a co-culture setup showed that PMD-Sen cells accelerate the migration compared to DDR-Sen cells (Fig. 7d and Extended Data Fig. 10). These results suggest that PMD-Sen cells have the potential to accelerate tissue wound healing in a paracrine manner.

#### PMD-Sen and Rep-Sen have PS-externalized spots and blebs

Because PS-externalized spots/blebs were observed after PMD (Fig. 1h.i and Extended Data Fig. 3a-d), we determined whether such spots/blebs exist in senescent cells. Indeed, Annexin V-positive PS-externalized spots/blebs were detected in PMD-Sen cells (Fig. 8a; SDS). Intriguingly, the replicative senescent cells (Rep-Sen cells), but not IR-treated DDR-Sen cells, had the Annexin V spots/blebs (Fig. 8a; cell division and IR). Analogous to the PMD-Sen cells, ESCRT-III (CHMP4A) signals were detected at  $21.5 \pm 5.0\%$  of PS-externalizing spots/blebs in Rep-Sen cells (Fig. 8b). Some PS-externalizing spots co-localize with projection-like structures in the bright-field image (Fig. 8a, white arrows): therefore. we performed a focused ion beam scanning electron microscope (FIB-SEM) analysis. We found that untreated young normal human fibroblasts (HCA2) had smooth plasma membranes (Fig. 8c, upper). In contrast, PMD-Sen cells had projections (Fig. 8c, lower). The heights of the projections were diverse (280 nm to  $2.5 \,\mu$ m). The widths of the projections were relatively uniform (100-130 nm). Together, these results demonstrate that PS-externalizing projections are the common feature of PMD-Sen cells and Rep-Sen cells but not of DDR-Sen cells.

To investigate whether the accumulation of PS-externalizing spots/blebs plays a causative role in cellular senescence induction, we observed the PS-externalizing spots/blebs after ESCRT-III (CHMP4B) overexpression. However, CHMP4B suppressed major cellular senescence features but did not significantly suppress the formation of PS-externalizing spots/blebs (Supplementary Fig. 6). These results suggest that the formation of PS-externalizing spots/blebs is not a cause of cellular senescence but a consequence of PMD.

#### Discussion

Here we report that PMD limits replicative lifespan in budding yeast and induces stress-dependent premature senescence in normal human fibroblasts. We developed a simple and universal method to induce PMD and designed a systematic genome-wide screen using budding yeast. Based on the screen, we found that PMD limits replicative lifespan in budding yeast and that overexpression of *VPS4* and *SNF7* extends it. In normal human fibroblasts, PMD induces premature senescence mediated by Ca<sup>2+</sup> and p53, and overexpression of CHMP4B suppresses it. The transition of mRNA expression profiles is different between PMD-Sen cells and DDR-Sen cells; PMD-Sen cells accelerate wound healing in vitro in a paracrine manner more than DDR-Sen cells. Our work proposes an underappreciated subtype of senescent cells: PMD-Sen cells.

#### ESCRT extends replicative lifespan in budding yeast

ESCRT is involved in various cellular processes, including cytokinesis, plasma membrane repair, nuclear membrane repair, multivesicular body formation, vacuolar membrane repair, autophagosome formation and microautophagy of the endoplasmic reticulum<sup>10,35,36</sup>. In the

Fig. 6 | Ca<sup>2+</sup> influx is necessary to induce PMD-dependent senescence, and<br/>KCI-dependent Ca<sup>2+</sup> influx is sufficient to induce cellular senescence.a-d, WI-38 cells were treated with 0.007% SDS with or without Ca<sup>2+</sup> chelatorBAPTA-AM (1 µM) for 24 h, washed and released into fresh medium. a, Cell<br/>number in a 6-cm-diameter dish was counted 10 d after SDS wash away. \*P < 0.05,</td>exact value: 0.0193, by two-tailed unpaired Student's t-test. b, SA-β-gal-positive<br/>cells were detected 10 d after SDS wash away. Scale bar, 50 µm. Graphs show<br/>quantification of SA-β-gal-positive cells (n > 100 cells). \*\*P < 0.01, exact value:<br/>0.0066, by two-tailed unpaired Student's t-test. c, Western blotting. The cells<br/>were collected at 6 d after wash away. Relative signal intensities are shown.<br/>\*P < 0.05 and \*\*P < 0.01, by one-way ANOVA with Dunnett' s test. Exact<br/>P value: p53\_Ctl versus SDS: 0.0179; p53\_Ctl versus SDS+BAPTA-AM: 0.7709;<br/>p21\_Ctl versus SDS: 0.0067; p21\_Ctl versus SDS+BAPTA-AM: 0.8175; p16\_Ctl versus<br/>SDS: 0.1591; p16\_Ctl versus SDS+BAPTA-AM: 0.0696. d, qPCR analysis of *lL6* and

present study, we found ESCRT in our screen for PMD response factors. Previously, ESCRT's involvement in replicative lifespan was reported by Yang et al.<sup>37</sup>. Yang et al. found that ESCRT mutants *did2* $\Delta$  and *vps24* $\Delta$ have a long replicative lifespan. Intriguingly, they also reported that another ESCRT mutant, *snf7* $\Delta$ , has a short replicative lifespan. These results strongly suggest a close and complex relationship between ESCRT functions and replicative lifespan regulation. Consistent with the findings of Yang et al., we show here that ESCRT is important for budding yeast replicative lifespan regulation based on two lines of evidence: (1) a yeast mutant lacking an ESCRT-III component (*snf7* $\Delta$ ) showed a short replicative lifespan (Fig. 2e and Extended Data Fig. 5a), and (2) *VPS4* overexpression and *SNF7* overexpression extended the replicative lifespan of budding yeast (Fig. 2f and Extended Data Fig. 5b).

ESCRT can contribute to the replicative lifespan of budding yeast by at least two scenarios that are not mutually exclusive. First, ESCRTdependent plasma membrane repair may prevent cell lysis and extend the replicative lifespan through the ESCRT's function in plasma membrane repair as established in human cells<sup>10,35</sup> and recently suggested in yeast<sup>38</sup>. Second, ESCRT-dependent vacuolar membrane repair may extend the replicative lifespan of budding yeast. This explanation also makes sense because vacuolar acidification defects limit the replicative lifespan in budding yeast<sup>39,40</sup>.

ESCRT is also involved in nuclear envelope repair<sup>10</sup>. However, we found that SDS treatment did not induce marked nuclear envelope deformation (Fig. 1f and Extended Data Fig. 2a), and ESCRT did not accumulate at the nuclear membrane after SDS treatment (Extended Data Fig. 3d, green). Therefore, it is unlikely that ESCRT contributes to the replicative lifespan via the nuclear envelope repair. Our study demonstrates that the PMD response shares many regulators, including ESCRT, with replicative lifespan regulation and that incomplete PMD response explains a mechanism underlying short replicative lifespan in budding yeast.

We demonstrate here that transient overexpression of ESCRT-III (CHMP4B) can suppress PMD-dependent acute cellular senescence in normal human fibroblasts (Fig. 4). However, we did not investigate the contribution of ESCRT to replicative lifespan in normal human fibroblasts. Further studies should be conducted to address whether ESCRT is involved in replicative lifespan regulation in higher eukaryotes.

#### Conserved stress-dependent cell cycle arrest mechanisms

Budding yeast has been used as a model of replicative lifespan regulation in eukaryotic cells. In telomere biology, at least three features are common between budding yeast and human cells: (1) the telomerase deficiency induces senescence in budding yeast<sup>41</sup>; (2) telomere shortening causes senescence via permanent activation of DNA damage checkpoints in both budding yeast and human cells<sup>42</sup>; and (3) telomere shortening-dependent DNA damage checkpoints can be bypassed due to adaptation in both human cells and budding yeast<sup>43,44</sup>. Thus, yeast can serve as a model to study basic senescence mechanisms associated with cell cycle regulation. However, there are limitations. For example,

*CCL2* gene expressions. RNA was isolated 5 d after wash away. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.005 and \*\*\*\**P* < 0.001, by one-way ANOVA with Dunnett's test. Exact *P* value: *IL6*\_Ctl versus SDS: <0.0001, *IL6*\_Ctl versus SDS+BAPTA-AM: 0.0003; *CCL2*\_Ctl versus SDS: 0.0043; *CCL2*\_Ctl versus SDS+BAPTA-AM: 0.0254. **e**,**f**, WI-38 cells were treated with 75 mM KCl for 24 h, washed and released into fresh medium. **e**, SA-β-gal-positive cells were detected using the cells 7 d after KCl wash away. Scale bar, 50 µm. Graphs show quantification of SA-β-galpositive cells (*n* > 100 cells). \**P* < 0.05, exact value: 0.0107, by two-tailed unpaired Student's *t*-test. **f**, Western blotting using cell lysates collected at indicated timepoints. Data in **a**-**e** are presented as mean (horizontal bars) ± s.d. (whiskers) of three biological replicates. **g**, Summary of the PMD-Sen mechanism. Ctl, control; NS, not significant; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related protein. yeast does not have the key senescence regulators, such as p53 and SASPs. Thus, yeast can serve as a model to study senescence-triggering cell cycle checkpoints but not all aspects of cellular senescence mechanisms.

## Molecular mechanisms underlying PMD-dependent senescence

We previously reported that PMD induces cyclin-dependent kinase (CDK) inhibitor Sic1 upregulation in budding yeast<sup>14</sup>. Analogous to





#### $Fig.\,7\,|\,Transcriptional\,profiling\,by\,RNA\text{-}seq\,reveals\,potential\,in\,vivo$

functions of PMD-dependent senescent cells. **a**, Heat maps generated by IPA comparison analysis show top canonical pathways affected by the differentially expressed mRNAs in PMD-Sen, Ca<sup>2+</sup>-Sen and DDR-Sen. See also Supplementary Fig. 4. PMD-Sen, PMD-dependent senescent cells; Ca<sup>2+</sup>-Sen, Ca<sup>2+</sup>-dependent senescent cells; DDR-Sen, DNA damage response-dependent senescent cells. Orange and blue indicate positive and negative activation *z*-score, respectively; white indicates no activation. Red outlines highlight the GP6 signaling pathway, which is inhibited in PMD-Sen and Ca<sup>2+</sup>-Sen but not in DDR-Sen. **b**, Heat maps generated by IPA comparison analysis show top canonical pathways affected by the SASP factors differentially expressed in PMD-Sen and Ca<sup>2+</sup>-Sen. See also

Supplementary Fig. 5. **c**, Overlapping canonical pathways in PMD-Sen and cutaneous wounds and in DDR-Sen and cutaneous wounds. RNA-seq results of cutaneous wounds were obtained from the public datasets (GSE141814). See also Extended Data Fig. 9. Day 0 and day 16 are shown. **d**, PMD-Sen cells accelerate wound healing in vitro in a paracrine manner more than DDR-Sen cells do. Young cells (recipient) were co-cultured with PMD-Sen cells (donor) or DDR-Sen cells (donor). Cell-free gaps (500  $\mu$ m) were made in the layer of young cells (recipient). Cell migration rate was calculated based on the filled cell-free area in 36 h. See also Extended Data Fig. 10. \**P* < 0.05, exact value: 0.0254, by two-tailed unpaired Student's *t*-test. Data in **d** are presented as mean (horizontal bars) ± s.d. (whiskers) of five biological replicates.

budding yeast, here we show that PMD promotes upregulation of the two CDK inhibitors, p21 and p16, in normal human fibroblasts (Fig. 3e and Extended Data Fig. 6e, f).

The next question is how PMD triggers the CDK inhibitor upregulation. We demonstrate that p53 was essential for the upregulation of p21 in normal human fibroblasts (Fig. 5d), but the DNA damage response pathway was dispensable for it (Fig. 5b,c). Consistent with these results, we found that p53 is phosphorylated at Ser33 but not at Ser15 (Fig. 3e). p53-Ser33 can be phosphorylated by several kinases, including p38 MAPK, Cdk5/7/9 and GSK3 $\beta^{45-48}$ . The kinase responsible for PMD-dependent phosphorylation of p53-Ser33 should be identified in the future.

Another group demonstrated that high cytosolic  $Ca^{2+}$  levels induce mitochondrial impairment, leading to upregulation of p53– p21 via cAMP-responsive element-binding protein (CREB) in the mice fibroblast-like cell line L929 (ref. 49). Consistently, we show here that (1) cytosolic  $Ca^{2+}$  increases after PMD<sup>1-3</sup> in the human normal fibroblasts WI-38 (Extended Data Fig. 8a–c), (2) BAPTA-AM, cell-permeable Ca<sup>2+</sup> chelator, attenuates PMD-Sen, and (3) enforced Ca<sup>2+</sup> influx by KCl was sufficient for inducing various senescence features (Fig. 6a–f). Therefore, Ca<sup>2+</sup> influx after PMD may mediate the upregulation of the p53–p21 axis in normal human fibroblasts. The absence of p53 in budding yeast suggests that the molecular details are not identical in budding yeast and human cells. Nonetheless, the upregulation of CDK inhibitors is a common mechanism promoting the PMD-dependent cell cycle arrest in both systems.

#### Transcriptomic profiling of the senescent cell subtypes

In this study, we revealed the time-resolved transcriptomic profiles of PMD-Sen cells in comparison with other senescent cell subtypes. We found that, although the transient PMD treatment significantly altered the transcriptomic profile (on day 0), most of the upregulated/downregulated pathways returned to the basal status (similar to the before-the-treatment sample) on 1–2 d after the treatment (Fig. 7).



Fig. 8 | Local PS externalization is associated with PMD-dependent and replicative senescence. a, SA- $\beta$ -gal (green) and Annexin V–Alexa Fluor 488 (red) signals were observed in HCA2 senescent cells induced by three different senescence induction methods (6 d after SDS wash away (SDS) and RS (cell division) and 6 d after IR). Scale bar, 50  $\mu$ m. White arrows, an Annexin V–positive projection. This experiment was independently repeated three times with similar results. **b**, Rep-Sen WI-38 cells were incubated with Annexin V–Alexa Fluor 647 conjugate, fixed and stained with CHMP4A antibody. The white rectangle

This 'gap' period delayed the senescence progression after PMD compared to the senescence progression after DNA damage. In the PMD-Sen cells, the senescence pathway was activated only on the third day after the treatment and later, suggesting that the cellular processes on 0-2 d are unique to the PMD-Sen cells.

#### Potential in vivo function of the PMD-Sen cells

Senescent cells accumulate around the wound-the tissue injury site-in vivo (mice and humans)<sup>16,50</sup>. This was shown by the increase of p21-positive, p16-positive or SA-β-gal-positive cells in response to wounding<sup>50-53</sup>. Those senescent cells contribute to optimal wound healing via SASP; the SASP mediates senescent cell clearance and tissue regeneration<sup>16,54</sup>. However, the origin of the senescent cells near the wound remained unclear. In the present study, we found that PMD induces the transient upregulation of wound healing SASP factors (Fig. 7b and Supplementary Fig. 5). Furthermore, we found that the pathways that were significantly changed in cutaneous wounded cells in mice skin were overlapped with PMD-Sen cells compared to DDR-Sen cells (Fig. 7c and Extended Data Fig. 9), and co-culturing with PMD-Sen cells accelerated migration speed of non-senescent cells in a paracrine manner (Fig. 7d). Together, these results are consistent with our idea that the PMD-Sen cells may contribute to tissue wound healing in vivo. This possibility needs to be further examined in future studies.

region in the left panels is enlarged in the right panels. Green, CHMP4A; red, Annexin V–Alexa Fluor 647 conjugate. BF, bright-field. White arrows, Annexin V and CHMP4A co-localization. Scale bar, left: 10 µm, right: 2 µm. This experiment was independently repeated three times with similar results. **c**, HCA2 cells were treated with 0.01% SDS for 24 h, washed and released into fresh medium. The cells were fixed after 6 d. SDS-treated (SDS, senescent) and untreated (Control, young) cells were analyzed by FIB-SEM. Scale bar, 1 µm. This experiment was independently repeated three times with similar results.

#### Local PS externalization in PMD-Sen and Rep-Sen cells

In our study, we observed PS-externalizing spots/blebs in PMD-Sen and Rep-Sen cells, but they were absent from DDR-Sen cells (Fig. 8a). Although PS externalization after PMD was previously reported<sup>17</sup>, the origin of the PS-externalizing spots/blebs in the Rep-Sen cells remains unknown. Plasma membrane repair and cytokinesis share the membrane resealing machinery, including ESCRT<sup>3,10</sup>. Therefore, repeated cytokinesis could induce the accumulation of the PS-externalizing spots/blebs during RS. This idea is consistent with our finding that PS was externalized at the bud scars, former cytokinesis sites, in budding yeast (Fig. 1d). Alternatively, the lipid scramblases<sup>55</sup> could be activated in Rep-Sen cells. In either case, our results demonstrate that the accumulation of PS-externalizing spots/blebs is a feature of PMD-Sen and Rep-Sen cells.

To address whether the formation of PS-externalizing spots/ blebs is a cause of cellular senescence, we observed externalized PS signals after overexpression of the membrane repair factor ESCRT-III (CHMP4B). This experiment was based on our assumption that if PS-externalizing spots/blebs cause cellular senescence, overexpression of membrane repair factor may remove them and bypass cellular senescence. Contrary to our initial assumption, we found that CHMP4B overexpression suppressed several features of cellular senescence, although it did not suppress the formation of PS-externalizing spots/blebs (Supplementary Fig. 6). These results suggest that the formation of PS-externalizing spots/blebs is not the cause of cellular senescence but the phenotype associated with two senescent cell subtypes, PMD-Sen cells and Rep-Sen cells. The remaining question was how CHMP4B was able to bypass cellular senescence without removing the PS-externalizing spots/blebs. One explanation could be that CHMP4B overexpression accelerates membrane resealing without removing PS-externalizing spots/blebs. Rapid membrane resealing may be sufficient to suppress drastic Ca<sup>2+</sup> influx and subsequent cellular senescence. The mechanism underlying CHMP4B dependent suppression of senescence induction should be further investigated in the future.

Overall, our results highlight an underappreciated subtype of senescent cells and raise many new questions to be addressed. Recent studies demonstrated that senolytic drugs clearing senescent cells ameliorate age-associated disorders<sup>56,57</sup>. Our study, therefore, may provide one potential explanation for the in vivo origin of senescent cells and serve as a basis for further studies aimed at developing new therapeutic strategies for PMD-associated diseases, including muscular dystrophy and Scott syndrome, as well as organismal aging.

#### Methods

#### Yeast media, strains and genetic manipulations

Standard procedures were employed for DNA manipulations as well as for *Escherichia coli* and *Saccharomyces cerevisiae* handling. YPD was used in most experiments. SD was used for live cell imaging. Yeast culture was performed at 25 °C unless otherwise indicated. The *S. cerevisiae* strains used in this study are listed in Supplementary Table 7.

#### **Penetration assay**

For the penetration assay in yeast cells, an overnight culture in YPD was refreshed and incubated for an additional 2–6 h until the optical density at 600 nm ( $OD_{600}$ ) reached 0.1–0.3. For Fig. 1a,b, the media were switched to YPD+20 mM EGTA, YPD+0.02% SDS, YPD+20 mM EGTA+0.02% SDS and control YPD for 15 min. All these media contained 2 ng ml<sup>-1</sup> DAPI. DAPI-positive cells were counted under Celld-iscoverer 7 (Zeiss, ZEN 2.6). For the penetration assay in human cells, DMEM containing DAPI, PI or FM1-43 was incubated with or without PMD stimuli.

#### Fluorescence imaging and image analysis in yeast

The laser damage assay was performed as described previously<sup>14</sup> with modifications. In brief, laser damage was induced using a laser scanning confocal microscope (LSM 780 NLO (Zeiss, ZEN 2.3)) equipped with a ×63 objective; a 405-nm, 488-nm and 561-nm laser; and a standard PMT and GaAsP detector. The region of interest (ROI) for laser IR with a 405-nm laser was set as approximately 0.5 µm in diameter. The laser power of the 405-nm laser was approximately 50% to induce local plasma membrane damage without cell lysis. A yeast culture grown overnight was refreshed and incubated for an additional 2–6 h until the OD<sub>600</sub> reached 0.1–0.3. Cells were then spotted onto an agarose bed (SD medium+1.2% agarose) on glass slides. Signal quantification was performed using Fiji/ImageJ software<sup>58</sup>.

#### Electron microscopy of yeast

Yeast cells sandwiched between copper grids were subjected to quick freezing using an isopentane/propane mixture of cold chemicals. The copper grid was diverged under liquid nitrogen gas atmosphere, soaked in 2% osmium/acetone solution and then stored at -80 °C for 2 d. The samples were placed at -20 °C for 3 h, at 4 °C for 1 h and then at room temperature. The samples were washed with acetone and subsequently with propylene oxide and then embedded in epoxy resin (Quetol 651). Observation was performed under a JEM-1011J (JEOL) or a JEM-1400Plus (JEOL) electron microscope.

#### Yeast genome-wide screen

Non-essential gene deletion library<sup>18</sup> and DAmP library in which mRNA levels of essential genes are decreased to 20-50% (ref. 19) were used in the yeast genome-wide screen. SDS sensitivity was determined using freshly prepared YPD+0.02% SDS plates. Cells grown on YPD plates for 3 d were pin-plated onto the SDS-containing plates and incubated at 30 °C for 3 d. The mutants identified in the first screening (249 mutants) were then freshly grown from -80 °C stock. Single colonies were isolated, streaked on YPD and YPD+0.02% SDS plates and incubated at 30 °C for 3-5 d. The incubation time was optimized for each strain. We obtained 109 mutants from the library, which were lethal on YPD+0.02% SDS plates. Subsequently, we independently constructed 119 mutants using our wild-type (BY23849) as a parental strain. At least three independent colonies were constructed per each mutant. Single colonies were isolated, streaked on YPD and YPD+0.02% SDS plates and incubated at 25 °C for 3-5 d (optimized for each strain). In the end, we obtained 48 mutants as confirmed hits, which were reproducibly lethal specifically on YPD+0.02% SDS plates.

#### Replicative lifespan analysis in yeast

Replicative lifespan analysis was performed as previously described<sup>21</sup>. In brief, newly formed daughter cells were separated after every cell division by a glass needle for tetrad analysis under the microscope. During the night, the plates were incubated at 12 °C. For the mechanical stress assay using a glass needle, a 12-mm-diameter cover glass was attached to the YPD plate, and mechanical stress was induced by hitting the cell on the glass needle against the cover glass (Extended Data Fig. 5d). The cells were then returned to the YPD plate, and the number of newly budded daughter cells was counted.

# Co-staining of Annexin V–Alexa Fluor 568 and Calcofluor white in yeast

Externalized PS detection in yeast was performed as previously described<sup>59</sup> with some modifications. Yeast cells were cultured in YPD for overnight, diluted to 1/10 in fresh YPD and then incubated for an additional 2–3 h. Cells were collected and washed once with Sorbitol buffer (35 mM potassium phosphate, pH 6.8, 0.5 mM MgCl<sub>2</sub>, 1.2 M sorbitol). Cells were incubated in 98  $\mu$ l of Sorbitol buffer + 2  $\mu$ l of 2.5 mg ml<sup>-1</sup> Zymolyase 100T (Seikagaku) for 90 min (wild-type) or 60 min (*pTEF1-VPS4*) at room temperature with gentle shaking. Cells were then washed once with Sorbitol buffer, resuspended in 19  $\mu$ l of Annexin V binding buffer + 1  $\mu$ l of Annexin V–Alexa Fluor 568 and incubated for 20 min at room temperature with gentle shaking. Supernatant was removed, and cells were suspended in 9.8  $\mu$ l of Annexin V binding buffer + 0.2  $\mu$ l of Calcofluor white stain (Sigma-Aldrich, Fluka). Images were acquired using an AXIO Observer.Z1 (Zeiss, ZEN 2.3).

#### Cell culture methods for human cells

Cell culture methods, senescence induction by IR and SA-β-gal staining were performed as previously described<sup>22,60</sup> with some modifications. In brief, cells were fixed for 3 min in 2% paraformaldehyde (PFA) and incubated for approximately 16 h at 37 °C with a staining solution containing 1 mg ml<sup>-1</sup>X-gal, 40 mM citric acid in sodium phosphate buffer (pH 6.0), 5 mMK<sub>4</sub>[Fe(CN)<sub>6</sub>]3H<sub>2</sub>O, 5 mMK<sub>3</sub>[Fe(CN)<sub>6</sub>], 150 mMNaCl and 2 mM MgCl<sub>2</sub>. Immunoblotting was performed following a standard protocol. Antibodies used in this study are listed in Supplementary Table 8, and antibody validation was performed by the distributors. Their webpage links are provided in the Reporting Summary. Images of blotted membranes were obtained by ChemiDoc Touch MP (Bio-Rad). HeLa cells and normal human fibroblasts (HCA2, WI-38 or BJ) were used (HeLa cell line, endocervical adenocarcinoma, female, from RIKEN BRC, cat. no. RCB0007, RRID: CVCL 0030; WI-38 cells, fibroblast, female, PDL36.6 from RIKEN BRC, cat. no. RCB0702, RRID: CVCL\_0579; WI-38 cells, fibroblast, female, PDL32.2 from JCRB, cat. no. IFO50075, RRID: CVCL\_0579; and BJ cells, fibroblast, male, PDL24.0 from the American Type Culture

Collection, cat. no. CRL-2522, RRID: CVCL 3653). HCA2 cells are normal human neonatal foreskin cells kindly gifted by I. Campisi (Buck Institute for Research on Aging) to M.N.<sup>60</sup> (male, PDL16.0). ATM inhibitor (KU-55933, Sigma-Aldrich), DNA-PK inhibitor (NU7026, Sigma-Aldrich) and cytosolic Ca<sup>2+</sup> chelator (BAPTA-AM, Alomone Labs) were added to the medium at a final concentration of 10  $\mu$ M, 10  $\mu$ M and 1  $\mu$ M, respectively. For Fig. 3a and Extended Data Fig. 6a,b, cells were grown in the medium with or without SDS (0.005–0.012%), and passage was performed every 3-4 d. After every passage, the cells were grown in the medium without SDS for 16 h and then switched to the SDS-containing medium. For SDSdependent senescence induction, cells were treated with the medium containing SDS (0.007-0.01%: optimized for cell strains/experimental conditions; Supplementary Fig. 3) for 24 h, washed twice with medium and covered with the fresh medium and then incubated for additional days as indicated in the figure. The SDS concentration was optimized for each experiment, depending on cell type and FBS lot. For reference, see Supplementary Fig. 8. SDS treatment shorter than 24 h did not efficiently induce cellular senescence, even when the concentration of SDS was increased. During the incubation, the medium was changed every 2 d. In Supplementary Fig. 3, the concentrations of SDS for inducing cellular senescence were determined by identifying the lethal concentration for each cell type, and then non-lethal concentrations, which do not induce cell death, were used. Each cell type was cultured in 10% FBS containing medium (DMEM, high glucose) with 0-0.015% SDS for 5 d, and the concentration of non-lethal, sublethal and lethal was determined. For SLO and silica treatment (Fig. 3f-i), WI-38 cells were treated with 200 ng ml<sup>-1</sup>SLO and 125 µg ml<sup>-1</sup> silica for 24 h, washed and released into a fresh medium. For laser damage-dependent senescence induction (Extended Data Fig. 6h-j), laser damage assay was performed as described above with modification. Laser damage was induced using a laser scanning confocal microscope, A1R (Nikon NIS-Elements 6.0), equipped with a ×60 objective; a 405-nm, 488-nm and 561-nm laser; and a standard PMT and GaAsP detector. The laser power of the 405-nm laser was 100%. Laser irradiated only at the periphery of the WI-38 cell without inducing detectable DNA damage. For KCl treatment (Fig. 6e, f), WI-38 cells were treated with 75 mM KCl for 24 h, washed and released into a fresh medium. For DXR treatment, the cells were incubated with 250 nM DXR (Cayman Chemical) for 24 h, washed and released into a fresh medium. For replicative senescence, the cells were split every 3-4 d until the cells stop proliferation. For knockdown experiments, WI-38 cells were transfected with siRNAs by Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific) or transduced with shRNA mediated by lentivirus. Target sequences are as follows. p53 siRNA (hs. Ri.TP53.13.3, Integrated DNA Technologies): GAGGUUGGCUCUGACU-GUACCACCA; p53 shRNA: ACTCCAGTGGTAATCTACT. Annexin V-Alexa Fluor 488 (Thermo Fisher Scientific) staining was performed following the manufacturer's instructions. Images were acquired using a BZ-9000 all-in-one fluorescence microscope (Keyence) or an LSM 780 confocal microscope (Zeiss). For time-lapse imaging (Extended Data Fig. 3c), WI-38 cells were incubated with the medium containing 0.008% SDS and 1:5,000 diluted pSIVA-IANBD (Novus Biological). Images were acquired by Celldiscoverer 7 (Zeiss, ZEN 2.6).

#### CHMP4B expression in WI-38 cells

A control plasmid (GFP) or GFP-CHMP4B was overexpressed in WI-38 cells by 4D-Nucleofector (Lonza, SE cell line solution, program EO-114) according to the manufacturer's instructions. One million cells were nucleofected with 0.5  $\mu$ g of DNA of either GFP or GFP-CHMP4B.

#### Co-staining of Annexin V and CHMP4A in human cells

Externalized PS was stained with Annexin V–Alexa Fluor 647 conjugate. After the PFA fixation, cells were treated with 0.1% saponin and 5% BSA for 40 min at room temperature. Subsequently, cells were incubated with primary and secondary antibodies. Images were taken with an SP8 confocal microscope (Leica LAS-X). WI-38 cells were incubated in 100 ng ml<sup>-1</sup> DAPI-containing DMEM with or without SDS. After washing away, cells were fixed with 4% PFA and resuspended in flow cytometry buffer (1× PBS with 2% FBS). Flow cytometric analysis was performed by Amnis ImageStream × Mk II (Millipore), and data were processed with FCS Express (De Novo Software). Cell aggregates and debris were removed by standard gating strategy.

#### Sample preparation for FIB-SEM

Normal human fibroblast cells (HCA2) were fixed with a 3% glutaraldehyde solution in 100 mM cacodylate buffer (pH 7.4) for 1 h at 4 °C. The cells were then washed with 7.5% sucrose, and then en bloc staining was performed following a procedure from National Center for Microscopy and Imaging Research (NCMIR) methods for three-dimensional (3D) electron microscopy (EM) (https://ncmir.ucsd.edu/sbem-protocol). Epon 812-embedded specimens were glued onto an aluminum FIB-SEM rivet with conductive epoxy resin. Next,  $15 \times 15$ -µm (1,000 × 1,000 pixels) images were acquired by an MI4000L (Hitachi High-Tech) at 20-nm intervals. More than 200 images were collected to reconstitute a single cell.

#### Stack alignment, segmentation and 3D representation

The image stacks were automatically aligned by Fiji/ImageJ software. Plasma membrane structure segmentation and 3D image reconstitution were performed manually with AMIRA version 5.6 software (FEI Visualization Science Group).

#### Ca<sup>2+</sup> imaging

WI-38 cells were plated on glass-bottom dishes. Cells were loaded with a cytosolic Ca<sup>2+</sup> indicator (5  $\mu$ M Cal Red R525/650, AAT Bioquest) and imaged using an SP8 confocal microscope (Leica LAS-X). Cytosolic Ca<sup>2+</sup> dynamics were tracked with three stack images around the focal plane. Fluorescence intensity (Ex 492 nm/Em 500–550 nm and Ex 492 nm/Em 625–675 nm) was recorded every 15 s. For quantification, z-stack images were prepared by Z projection tools (sum slices), and the whole area of each cell was selected by ROI selection tools (Fiji/ImageJ). The average fluorescence ratio (500–550 nm / 625–675 nm) was measured and calculated as *F* value.  $\Delta F$  values were calculated from ( $F - F_0$ ) where  $F_0$  values were defined by averaging four frames before stimulation.

#### RNA extraction and qRT-PCR analyses

Cells were lysed in TRIzol, RNA was extracted and purified using an RNA Clean and Concentrator-5 Kit (Zymo Research) following the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using SuperScript IV VILO Master Mix (Thermo Fisher Scientific). The expression of target genes was determined using QuantStudio1Real-Time PCR system (Thermo Fisher Scientific). PCR was performed using PowerTrack SYBR Green Master Mix (Thermo Fisher Scientific) with primer pairs as listed in Supplementary Table 9. The data were statistically analyzed using SPSS version 21.0 software (IBM). One-way ANOVA and Tukey-Kramer test were used to check the significant changes of gene expression. NormFinder software was used to determine the stability values of the reference gene. Changes in gene expression, expressed as fold change, were calculated using the  $\Delta\Delta$ Ct method, where ACTB was used as a reference gene for normalizing the expression. The nested scatter plot was generated to show the fold changes of each replicate (GraphPad Prism).

#### **EdU staining**

For RS, WI-38 cells were passaged until they lost the ability to proliferate and became fully senescent around population doubling level (PDL) 52. For the PMD-Sen and DDR-Sen, young WI-38 cells were treated with SDS or DXR containing medium for 24 h. A Click-iT Plus EdU Cell Proliferation Kit for Imaging, Alexa Fluor 647 dye (Thermo Fisher Scientific) was used for the detection of DNA synthesis. Cells were labeled with 10  $\mu$ M EdU for 24 h and then treated according to the manufacturer's instructions. Images were obtained with AXIO Observer 7 (Zeiss, ZEN 3.1).

#### mRNA-seq

All samples were sequenced by a NovaSeq 6000 (Illumina). Paired-end cDNA libraries were sequenced with a 2 × 150-bp configuration. Each sample was sequenced at a depth of more than 20 million paired-end reads. RNA sequencing (RNA-seq) datasets have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database with accession number GSE222400.

#### Pathway and biological functions analyses using IPA software

IPA software was used to predict networks that are affected by the differentially expressed genes. Details of the identified genes, their quantitative expression values and P values were imported into IPA software. The 'Core Analysis' function included in IPA software was used to interpret the data in the context of biological processes, pathways and networks<sup>61</sup>. Both upregulated and downregulated genes were defined as value parameters for the analysis. Each gene identifier was mapped to its corresponding protein object and was overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. A network of proteins was then algorithmically generated based on their connectivity. Right-tailed Fisher's exact test was used to calculate a P value to indicate the probability of each biological function being assigned to the network by chance. IPA comparison analysis was performed in accordance with our established comparison analyses<sup>62</sup>. A heat map was generated based on the activation z-scores. The public datasets for the cutaneous wound (Fig. 7c) were adopted from regenerative samples (GSM4213633) in GSE141814 (ref. 34). The overlap of the pathways was visualized by the open access application BioVenn<sup>63</sup>.

#### Co-culture and migration assays

To create cell-free gaps, ibidi two-chamber inserts were placed in sixwell plates, and WI-38 cells were seeded into these chambers. For coculturing, PMD-Sen and DDR-Sen cells were seeded onto transwell inserts (Extended Data Fig. 10a). The membrane of the transwell inserts had 0.4- $\mu$ m pores, facilitating the transfer of soluble proteins and small extracellular vesicles. Images were captured at 0 h and 36 h after cellfree gap establishment. The migration rate ( $\mu$ m<sup>2</sup> per hour) was determined as previously described<sup>64</sup>. In brief, the gap area of each timepoint was calculated as a function of time to derive the cell migration rate.

#### Statistics and reproducibility

Microsoft Excel 365 version 1711 or later, GraphPad Prism 9, IPA Fall 2021 or later and SPSS version 21.0 software were used for data presentation and statistical analysis. No explicit sample size calculation was performed. We followed community norms, and sample sizes are similar to those reported in previous publications<sup>15,22</sup>. Exact sample sizes / number of independent experiments are given in the corresponding figure legends, extended data figure legends, supplementary figure legends and supplementary data. For biochemical and spectrometric experiments, each experiment was independently repeated multiple times. In principle, at least three independent experiments were performed for each assay to verify the reproducibility of the results. mRNA-seq was performed with two independent samples. No data were excluded from analysis. All cell culture experiments were randomly assigned to experimental conditions. For microscopic images, the image fields of immunofluorescence and TEM observations and SA-β-gal staining were randomly acquired. Data distribution was assumed to be normal, but this was not formally tested; therefore, data distributions are visualized in each figure. Data collection and analysis were not performed blinded to the conditions of the experiments. The statistical test used to determine the significance of differences is indicated in the figure legends.

#### **Reporting summary**

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

#### **Data availability**

The RNA-seq dataset generated and analyzed during the current study is available in the NCBI GEO repository (www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE222400). Source data are provided with this paper. The rest of the data generated or analyzed during this study are included in the published article and its supplementary information files. Externally generated data can be obtained from the following resources: www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141814 and www.saspatlas.com.

#### References

- Andrews, N. W., Almeida, P. E. & Corrotte, M. Damage control: cellular mechanisms of plasma membrane repair. *Trends Cell Biol.* 24, 734–742 (2014).
- McNeil, P. L. & Steinhardt, R. A. Plasma membrane disruption: repair, prevention, adaptation. *Annu. Rev. Cell Dev. Biol.* 19, 697–731 (2003).
- Sonnemann, K. J. & Bement, W. M. Wound repair: toward understanding and integration of single-cell and multicellular wound responses. *Annu. Rev. Cell Dev. Biol.* 27, 237–263 (2011).
- 4. Bashir, R. et al. A gene related to *Caenorhabditis elegans* spermatogenesis factor *fer-1* is mutated in limb-girdle muscular dystrophy type 2B. *Nat. Genet.* **20**, 37–42 (1998).
- Suzuki, J., Umeda, M., Sims, P. J. & Nagata, S. Calcium-dependent phospholipid scrambling by TMEM16F. *Nature* 468, 834–838 (2010).
- 6. Wu, N. et al. Critical role of lipid scramblase TMEM16F in phosphatidylserine exposure and repair of plasma membrane after pore formation. *Cell Rep.* **30**, 1129–1140 (2020).
- Burkel, B. M., Benink, H. A., Vaughan, E. M., von Dassow, G. & Bement, W. M. A Rho GTPase signal treadmill backs a contractile array. *Dev. Cell* 23, 384–396 (2012).
- McNeil, P. L. & Kirchhausen, T. An emergency response team for membrane repair. *Nat. Rev. Mol. Cell Biol.* 6, 499–505 (2005).
- 9. Nakamura, M. et al. Into the breach: how cells cope with wounds. *Open Biol.* **8**, 180135 (2018).
- Vietri, M., Radulovic, M. & Stenmark, H. The many functions of ESCRTs. Nat. Rev. Mol. Cell Biol. 21, 25–42 (2020).
- 11. Zhen, Y., Radulovic, M., Vietri, M. & Stenmark, H. Sealing holes in cellular membranes. *EMBO J.* **40**, e106922 (2021).
- 12. Cookson, B. T. & Brennan, M. A. Pro-inflammatory programmed cell death. *Trends Microbiol.* **9**, 113–114 (2001).
- 13. Wang, L., Qin, X., Liang, J. & Ge, P. Induction of pyroptosis: a promising strategy for cancer treatment. *Front. Oncol.* **11**, 635774 (2021).
- Kono, K., Al-Zain, A., Schroeder, L., Nakanishi, M. & Ikui, A. E. Plasma membrane/cell wall perturbation activates a novel cell cycle checkpoint during G1 in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 113, 6910–6915 (2016).
- Kono, K., Saeki, Y., Yoshida, S., Tanaka, K. & Pellman, D. Proteasomal degradation resolves competition between cell polarization and cellular wound healing. *Cell* **150**, 151–164 (2012).
- Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. *Dev. Cell* **31**, 722–733 (2014).
- 17. Draeger, A., Monastyrskaya, K. & Babiychuk, E. B. Plasma membrane repair and cellular damage control: the annexin survival kit. *Biochem. Pharmacol.* **81**, 703–712 (2011).
- Winzeler, E. A. et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285, 901–906 (1999).

- Breslow, D. K. et al. A comprehensive strategy enabling highresolution functional analysis of the yeast genome. *Nat. Methods* 5, 711–718 (2008).
- Weng, M.-P. & Liao, B.-Y. modPhEA: model organism phenotype enrichment analysis of eukaryotic gene sets. *Bioinformatics* 33, 3505–3507 (2017).
- Sinclair, D. A. Biological Aging: Methods and Protocols (ed. Tollefsbol, T. O.) 49–63 (Springer, 2013).
- 22. Johmura, Y. et al. Necessary and sufficient role for a mitosis skip in senescence induction. *Mol. Cell* **55**, 73–84 (2014).
- 23. Rufini, A., Tucci, P., Celardo, I. & Melino, G. Senescence and aging: the critical roles of p53. *Oncogene* **32**, 5129–5143 (2013).
- Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science* 281, 1677–1679 (1998).
- Hafner, A., Bulyk, M. L., Jambhekar, A. & Lahav, G. The multiple mechanisms that regulate p53 activity and cell fate. *Nat. Rev. Mol. Cell Biol.* 20, 199–210 (2019).
- Shieh, S.-Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. *Cell* **91**, 325–334 (1997).
- 27. Bulavin, D. V. et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. *EMBO J.* **18**, 6845–6854 (1999).
- Kishi, H. et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser<sup>33</sup> by activated p38<sup>MAPK</sup> without phosphorylation at Ser<sup>15</sup> and Ser<sup>20</sup>. J. Biol. Chem. **276**, 39115–39122 (2001).
- d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 426, 194–198 (2003).
- Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogeneinduced DNA damage model for cancer development. Science 319, 1352–1355 (2008).
- Leong, W. F., Chau, J. F. L. & Li, B. p53 deficiency leads to compensatory up-regulation of p16<sup>INK4a</sup>. *Mol. Cancer Res.* 7, 354–360 (2009).
- Martin, N. & Bernard, D. Calcium signaling and cellular senescence. Cell Calcium 70, 16–23 (2018).
- Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. *PLoS Biol.* 18, e3000599 (2020).
- 34. Chen, C.-J. et al. Single-cell RNA-seq analysis reveals cellular functional heterogeneity in dermis between fibrotic and regenerative wound healing fates. *Front. Immunol.* **13**, 875407 (2022).
- 35. Jimenez, A. J. et al. ESCRT machinery is required for plasma membrane repair. Science **343**, 1247136 (2014).
- Schäfer, J. A. et al. ESCRT machinery mediates selective microautophagy of endoplasmic reticulum in yeast. *EMBO J.* 39, e102586 (2020).
- Yang, J. et al. Systematic analysis of asymmetric partitioning of yeast proteome between mother and daughter cells reveals 'aging factors' and mechanism of lifespan asymmetry. *Proc. Natl Acad. Sci. USA* **112**, 11977–11982 (2015).
- Schmidt, O. et al. TOR complex 2 (TORC2) signaling and the ESCRT machinery cooperate in the protection of plasma membrane integrity in yeast. J. Biol. Chem. 295, 12028–12044 (2020).
- Hughes, A. L. & Gottschling, D. E. An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. *Nature* 492, 261–265 (2012).
- Hughes, C. E. et al. Cysteine toxicity drives age-related mitochondrial decline by altering iron homeostasis. *Cell* 180, 296–310 (2020).

- Lundblad, V. & Szostak, J. W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57, 633–643 (1989).
- 42. Henninger, E. & Teixeira, M. T. Telomere-driven mutational processes in yeast. *Curr. Opin. Genet. Dev.* **60**, 99–106 (2020).
- 43. Coutelier, H. et al. Adaptation to DNA damage checkpoint in senescent telomerase-negative cells promotes genome instability. *Genes Dev.* **32**, 1499–1513 (2018).
- 44. Syljuåsen, R. G., Jensen, S., Bartek, J. & Lukas, J. Adaptation to the ionizing radiation–induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. *Cancer Res.* **66**, 10253–10257 (2006).
- Ko, L. J. et al. p53 is phosphorylated by CDK7-cyclin H in a p36<sup>MAT1</sup>dependent manner. *Mol. Cell. Biol.* **17**, 7220–7229 (1997).
- Lee, J.-H., Kim, H.-S., Lee, S.-J. & Kim, K.-T. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J. Cell Sci. 120, 2259–2271 (2007).
- 47. Radhakrishnan, S. K. & Gartel, A. L. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. *Cell Cycle* **5**, 519–521 (2006).
- 48. Turenne, G. A. & Price, B. D. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. *BMC Cell Biol.* **2**, 12 (2001).
- 49. Arnould, T. et al. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. *EMBO J.* **21**, 53–63 (2002).
- 50. Bird, T. G. et al. TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. *Sci. Transl. Med.* **10**, eaan1230 (2018).
- 51. Chia, C. W. et al. Age-associated expression of p21and p53 during human wound healing. *Aging Cell* **20**, e13354 (2021).
- 52. Jun, J.-I. & Lau, L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. *Nat. Cell Biol.* **12**, 676–685 (2010).
- 53. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. *Cell* **134**, 657–667 (2008).
- 54. Ritschka, B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. *Genes Dev.* **31**, 172–183 (2017).
- Nagata, S., Sakuragi, T. & Segawa, K. Flippase and scramblase for phosphatidylserine exposure. *Curr. Opin. Immunol.* 62, 31–38 (2020).
- 56. Ge, M. et al. Senolytic targets and new strategies for clearing senescent cells. *Mech. Ageing Dev.* **195**, 111468 (2021).
- Johmura, Y. et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science 371, 265–270 (2021).
- 58. Schindelin, J. et al. Fiji: an open-source platform for biologicalimage analysis. *Nat. Methods* **9**, 676–682 (2012).
- 59. Madeo, F., Fröhlich, E. & Fröhlich, K.-U. A yeast mutant showing diagnostic markers of early and late apoptosis. *J. Cell Biol.* **139**, 729–734 (1997).
- Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl Acad. Sci. USA* 92, 9363–9367 (1995).
- 61. Razali, N., Aziz, A. A., Lim, C. Y. & Junit, S. M. Investigation into the effects of antioxidant-rich extract of *Tamarindus indica* leaf on antioxidant enzyme activities, oxidative stress and gene expression profiles in HepG2 cells. *PeerJ* **3**, e1292 (2015).
- 62. Ahmed, H. et al. LC-MS/MS proteomic study of MCF-7 cell treated with dox and dox-loaded calcium carbonate nanoparticles revealed changes in proteins related to glycolysis, actin signalling, and energy metabolism. *Biology* **10**, 909 (2021).
- 63. Hulsen, T. BioVenn—an R and Python package for the comparison and visualization of biological lists using area-proportional Venn diagrams. *Data Science* **4**, 51–61 (2021).

 Jonkman, J. E. et al. An introduction to the wound healing assay using live-cell microscopy. *Cell Adh. Migr.* 8, 440–451 (2014).

#### Acknowledgements

We are grateful to T. Hunt, D. Pellman, Z. Storchová, I. Fukunaga, A. Nishiyama, M. Shimada, T. Kiyomitsu, R. Hatakeyama and S. Yoshida for critical reading of the manuscript; to Y. Hamamura for live imaging analysis; to S. Arai and S. Enomoto for FIB-SEM analysis; and to H. I. Wen, T. Inden, C. Yamada-Namikawa, K. Mori, M. Akiyama, Y. Tsukui, Y. Matsui, K. Koizumi, T. Mochizuki, S. Komoto and P. Barzaghi for technical assistance. A portion of this work was conducted in the Institute of Transformative Bio-Molecules (WPI-ITbM) at Nagoya University, supported by the Japan Advanced Plant Science Network. A portion of this work was supported by the NIMS microstructural characterization platform as a program of the Nanotechnology Platform of MEXT Japan. A portion of this work was performed with the help of OIST imaging section members. This study was supported by MEXT/JSPS KAKENHI under grant numbers JP26250027, JP22118003 and JP16K15239 and by AMED under grant numbers JP17cm0106122, JP17fk0310111 and JP17gm5010001 as well as by the Ono Medical Research Foundation, the Princess Takamatsu Cancer Research Fund and the Relay For Life Japan Cancer Society to M.N. This study was also supported by MEXT/ JSPS KAKENHI under grant numbers 15K19012, 17H04045, 20H03440, JST-PRESTO and JPMJPR1686; the Naito Foundation Subsidy for Female Researchers; JST-COI-NEXT JPMJPF2205 to K.K.; MEXT/JSPS KAKENHI under grant number 19K21598 to Y. Moriyama; and MEXT/ JSPS KAKENHI under grant number 22J21762 to K.S. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

### **Author contributions**

K.K. planned and interpreted the overall studies. K.K., S.S., K.S. and Y.Y. performed yeast experiments. K.K., Y.J., Y. Moriyama., K.S., N.R., Y.C., K.N., Y. Masukagami and H.B. performed human cell culture experiments. H.T. performed and interpreted yeast electron microscopy experiments. Y. Moriyama performed and interpreted FIB-SEM experiments. K.K., Y.S. and T.H. performed and interpreted laser damage experiments. K.K., Y.J., Y. Moriyama., K.S., N.R., Y.C., K.N. and M.N. prepared the figures. K.K., M.N., K.S., Y. Moriyama, Y. Masukagami and N.R. wrote the manuscript, with editing by all authors.

#### **Competing interests**

The authors declare no competing interests.

#### **Additional information**

**Extended data** is available for this paper at https://doi.org/10.1038/ s43587-024-00575-6.

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s43587-024-00575-6.

**Correspondence and requests for materials** should be addressed to Keiko Kono.

**Peer review information** *Nature Aging* thanks Jesper Nylandsted, Yi Zhang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2024



**Extended Data Fig. 1 | SDS induces local plasma membrane and cell wall damage in budding yeast. (a)** Wild type yeast cells were cultured in YPD incubated with or without 0.02% SDS for 3 hr, and then stained with 20  $\mu$ g/ml calcofluor white for 5 min. The values under the images are % cells with spot signals. Mean(SD) of four independent experiments. n > 100 cells/each experiment. *p* < 0.001 by 2-tailed unpaired Student's *t*-test. Scale bar, 5  $\mu$ m. **(b)** Wild type yeast cells were cultured at 25°C under the microscope with 10  $\mu$ g/ml calcofluor white and then laser damage was induced (yellow stars). Yellow

arrows, calcofluor white signal accumulation. The numbers at the upper-left corner indicate time (min). Images were taken at 30 sec intervals. Scale bar, 2 µm. This experiment was independently repeated three times with similar results. This experiment was independently repeated three times with similar results. **(c)** Wild type yeast cells expressing Pkc1-GFP or Myo2-GFP were incubated with YPD containing 0.02% SDS for 30 min. The numbers at the lower-left corners indicate % of cells with a polarized GFP signal at the tip of daughter cells. n > 200.



Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | SDS induces plasma membrane damage in human

**cells. (a)** Representative images of DAPI penetrated HeLa cells upon 0.008% SDS treatment over time. HeLa cells were cultured in DAPI-containing medium with or without 0.008% SDS. Scale bar, 20  $\mu$ m. This experiment was independently repeated three times with similar results. **(b)** A representative data set of DAPI penetration assay. DAPI positive cells were counted at indicated time points. Cell number: 1hr Untreated (n = 217), 1hr SDS (n = 208), 4hr Untreated (n = 211), 4hr SDS (n = 219), 8hr Untreated (n = 208), 8hr SDS (n = 212), 24hr Untreated (n = 212), 24hr SDS (n = 216). Data points are shown with Mean(SD). **(c)** Average DAPI intensity of three independent experiments as in (b). Untreated control and 0.008% SDS treatment were significantly different. *P* value: \*<0.05, 1hr:

0.001066, 4hr: 0.000079, 8hr: 0.000018, 24hr: 0.000438, using two-sided multiple Welch's *t*-test with Benjamini, Krieger and Yekutieli correction. Data points are shown with Mean(SD). **(d)** Flow cytometric analyses of penetrated DAPI signals are shown by histogram overlays. WI-38 cells were cultured in DAPI-containing medium with or without SDS (0.0085%). Cell number: untreated 1hr (n = 5029), untreated 24hr (n = 5025), SDS 1hr (n = 5007), SDS 24hr (n = 5192). **(e)** Live-cell imaging was performed using HeLa cells cultured in FM1-43-containing medium (no FBS) with or without 0.002% SDS. The cytosolic FM1-43 signals were quantified (8 cells per each group). n = 10 cells examined over 2 independent experiments. Graphs are shown as Mean(SD).



**Extended Data Fig. 3 | SDS induces local PS externalization that colocalizes with CHMP4A on the plasma membrane of human cells. (a)** A representative data set of Annexin V spots analyses. The number of Annexin V positive spots per cell was counted. n = 60. Data points are shown with Mean(SD). (b) Relative Annexin V signals of entire cells were quantified. Cell number: No SDS (n = 100), SDS 1hr (n = 65). Data points are shown with Mean(SD). (c) WI-38 cells were cultured in the medium with 0.008% SDS and pSIVA under the fluorescent microscope. pSIVA binds to externalized PS. Arrow heads, pSIVA positive spots. Yellow arrows, pSIVA positive blebs. The white rectangle region is enlarged

in right panels. Scar bar, 20  $\mu$ m (left), 5  $\mu$ m (right). Merged images of pSIVA and Bright Field. This experiment was independently repeated two times with similar results. (d) HeLa cells were treated with 0.008% SDS for 1 hr. The cells were incubated with Annexin V-Alexa Fluor 647 conjugate, fixed, and stained with CHMP4A antibody. The white rectangle region in upper panels is enlarged in lower panels. Green: CHMP4A, Red: Annexin V, Alexa Fluor 647 conjugate, BF: Bright Field. White arrows indicate the colocalization of green and red signals. Scale bars, 10  $\mu$ m (upper), 2  $\mu$ m (lower). This experiment was independently repeated five times with similar results.



Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4** | **Identification and characterization of factors required for plasma membrane/cell wall damage response in budding yeast. (a and b)** Yeast gene deletion mutants were cultured in YPD at 25° C and then incubated with YPD containing 0.02% SDS. Samples were collected at 30 min intervals and spread onto YPD plates. The number of colonies was counted after 2-3 days. Graphs are shown as Mean(SD) of 3 independent experiments. (c) Yeast mutants were treated as in (a) except for the usage of YPD (pH 5.0). **(d)** Yeast mutants were treated as in (a). **(e)** Yeast gene deletion mutants were cultured in YPD at 25° C and then incubated with YPD containing 0.02% SDS for 30 min. Data are shown as Mean(SD) of 3 independent experiments. > 300 cells/sample. For statistical analysis, Control cells vs. +SDS cells were compared. *P* values: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001, by 2-tailed unpaired Student's *t*-test. Exact *P* value: *vma1*: 0.0146, *vma13*: 0.0062, *vps1*6: 0.0129, *erg2*: 0.0081, *vps4*: 0.0006. (f) Wild type (Control) and  $vma1\Delta$  expressing Cr21-GFP were cultured under the microscope and subjected to laser damage (yellow stars). Images were taken in 30 sec intervals. The numbers at the upper-right corners indicate the time (min). Scale bar, 2 µm. (g) Quantification of (f). Data are shown as Mean(SEM) of 8 independent experiments. (h) Wild type yeast expressing Lact-C2-GFP were cultured under the microscope and subjected to the laser damage as in (f). Relative signal intensity is shown in rainbow pseudocolor. The numbers at the left-top corners indicate the time (min). Arrows: the GFP signal accumulation at the laser damage sites. Scale bar, 2 µm. (i) Quantification of (h). Mean of 10 independent experiments. (j) Wild type (Control),  $pep3\Delta$  and  $vps34\Delta$  expressing Pkc1-GFP were cultured under the microscope and subjected to laser damage as in (f). Scale bar, 2 µm. (k) Quantification of (j). Control (n = 5), pep3 (n = 3), vps34 (n = 4) independent cells were examined. Mean(SEM).



**Extended Data Fig. 5** | **plasma membrane damage limits replicative lifespan in budding yeast. (a-c)** Yeast replicative life span was measured with another biological replicate, and results were consistent with Fig. 2 (e-g). Cell number: (a) Wild type (n = 24), vps34 $\Delta$  (n = 24), snf7 $\Delta$  (n = 24), erg2 $\Delta$  (n = 24). (b) Wild type (n = 48), VPS4 (n = 48), SNF7 (n = 48). (c) Wild type (n = 24), SDS (n = 24), SDS+VPS4 (n = 24), SDS+SNF7 (n = 24). Pvalue: \*<0.05, \*\*<0.01, \*\*\*\*<0.001 by two-sided Wilcoxon Rank-sum test. Exact Pvalue: (a) WT vs. *vps34* $\Delta$ : 0.0005, WT vs. *snf7* $\Delta$ : <0.0001, WT vs. *erg2* $\Delta$ : 0.0008. (b) WT vs. *VPS4*: 0.0209, WT vs. *SNF7*: 0.0465. (c) WT vs. SDS: <0.0001, WT vs. SDS+*VPS4*: 0.0473, WT vs. SDS+*SNF7*: 0.0158. (d) A schematic image of mechanical damage induced by a glass needle and a glass coverslip. (e) The viability of the yeast cells was measured. Mean(SD) of 3 biological replicates. n = 40. (f) WT yeast cells were subjected to the replicative life span measurement with or without mechanical damage. Median values are shown. Cell number: Wild type (n = 24), Glass (n = 24). *P* value: \*\*\*\*<0.001, exact value: <0.0001, by two-sided Wilcoxon Rank-sum test.



Extended Data Fig. 6 | See next page for caption.

**Extended Data Fig. 6** | **Transient plasma membrane damage induces premature senescence in normal human fibroblasts. (a and b)** PDL of human normal fibroblasts with continuous SDS treatment. Human normal fibroblasts (a: HCA2, b: BJ) were cultured with or without SDS (0.006-0.012%; indicated on the right). (c) Relative cell numbers of HCA2 cells after the transient (24 hours) SDS treatment. More than 1x10<sup>5</sup> cells were quantified. HCA2 cells were incubated in the medium with (SDS) or without (-) 0.01% SDS for 24 hours, washed, and released into fresh medium. Data are shown as Mean(SD) of 3 independent experiments. (d) HCA2 cells were treated with 0.01% SDS for 24 hours, washed, and released into fresh medium. SA-β-gal positive cells were detected using the cells 6 days after SDS wash away. Scale bar, 50 μm. Graphs show quantification of SA-β-gal positive cells (n > 100). Data are shown as Mean(SD) of >3 independent experiments. *P* value: \*\*<0.01, exact value: 0.0032, by 2-tailed unpaired Student's *t*-test. (**e and f**) Western blotting using cell lysates of HCA2 cells treated with 0.01% SDS for 24 hours or 10 Gy IR (Irradiation, control). This experiment was independently repeated three times with similar results. **(g)** PI penetration assay was performed with 24 hours treatment of 200 ng/ml streptolysin O (SLO), 125 µg/ml silica ( $\varphi = 0.8 \mu$ m) (Silica). n > 100 cells. *P* value: \*\*\*\*<0.001, Control vs. SLO: <0.0001, Control vs. Silica: <0.0001, by One-way ANNOVA, Dunnett. **(h)** Cell number of WI-38 cells in 35 mm glass bottom dish was counted 10 days after laser irradiation. *P* value: \*<0.05, exact value: 0.026, by 2-tailed unpaired Student's *t*-test. **(i)** SA-β-gal positive cells were detected 16 days after laser irradiation. Scale bar, 50 µm. Graphs show quantification of SA-β-gal positive cells. n > 100 cells. *P* value: \*<0.05, exact value: 0.0227, by 2-tailed unpaired Student's *t*-test. **(j)** WI-38 cells just after laser irradiation or cells at 24 hours after DXR treatment were stained with γH2AX (red) and with DAPI (blue). Scale bar, 50 µm. Graphs are shown as Mean(SD) of 3 biological replicates.



Extended Data Fig. 7 | See next page for caption.

Extended Data Fig. 7 | PMD-Sen induction requires p53 and doxorubicin does not induce plasma membrane damage. (a) HCA2 cells at 24 hours after SDS wash away (SDS), cells at 4 hours after 10 Gy Irradiation treatment (IR), and untreated cells (–) were stained with  $\gamma$ H2AX (red) and with DAPI (blue). Scale bar, 50  $\mu$ m. This experiment was independently repeated three times with similar results. (b-d) Western blotting of p53 and p21. This experiment was independently repeated three times with similar results. (b and c) HCA2 cells were treated as in Fig. 3f with or without (b) ATM inhibitor KU-55944 (10  $\mu$ M) or (c) DNA-PK inhibitor (10  $\mu$ M). (d) Cells expressing doxycycline-inducible control shRNA (shControl) or p53 shRNA (shp53) with doxycycline (1  $\mu$ g/ml) were treated with 0.01% SDS for 24 hours. After SDS wash away, cells lysates prepared at the indicated times were subjected to immunoblotting using the antibodies indicated. (e) SA- $\beta$ -gal positive cells were counted on 6 days after SDS wash away. n = 200 cells examined over 3 biologically independent experiments. Data are shown as Mean(SD). *P* value: \*\*<0.01, exact value: 0.0056, by 2-tailed unpaired Student's *t*-test. (f) Representative images of DAPI penetration upon 0.008% SDS treatment (SDS) and 250 nM DXR for 24 hr. WI-38 cells were cultured in DAPIcontaining medium with or without 0.008% SDS or 250 nM DXR. Scale bar, 20  $\mu$ m. (g) A representative data set of DAPI penetration assay. DAPI positive cells were counted at indicated time points. Cell number: Control (n = 248), SDS (n = 166), DXR (n = 210). \*\*\*\*; *p* < 0.0001, Ctl vs. SDS: <0.0001, Ctl vs. DXR: 0.1928, by oneway ANOVA. ns: not significant. Scale bar, 100  $\mu$ m. Data are shown as Mean(SEM)



Extended Data Fig. 8 | See next page for caption.

Extended Data Fig. 8 | Cytosolic Ca<sup>2+</sup> levels are increased after SDS treatment and Plasma membrane damage and Ca<sup>2+</sup>-influx induce cellular senescence. (a) Representative ratiometric images of cytosolic Ca<sup>2+</sup> (Cal Red R525/650)

(a) Representative rationetric images of cytosonic Ca<sup>-1</sup> (Car Red R525/630) in WI-38 cells before or 1.5 min after addition of 0.0095% SDS. Fluorescence intensity was shown as a rainbow pseudocolor. Scale bar, 20 µm. (b) Cal Red R525/650 signals in WI-38 cells after addition of 0.0095%. n = 8. (c) Relative cytosolic Ca<sup>2+</sup> levels in cells treated with 0.0095% SDS for one hour (n = 26 cells) compared with untreated cells (n = 32 cells) over 3 independent experiments. *P* value: \*\*\*\*<0.0001, by 2-tailed unpaired Student's *t*-test. Mean(SEM). (**d**) The experimental design. (**e and f**) SA-β-gal positive cells were detected using WI-38 cells treated with 0.008% SDS, 75 mM KCl, and 250 nM DXR for 24 hours. The cells were washed and stained at the indicated time points. PC, Phase Contrast. Scale bar, 500  $\mu$ m. n > 80 cells. The precise cell numbers are shown in Statistical Source Data file. 3 biological replicates. Mean(SD) is shown. (**g**) Western blotting using cell lysates of the WI-38 cells used in (e) and (f). This experiment was independently repeated three times with similar results.



**Extended Data Fig. 9** | **The overlapping pathways between PMD-Sen and cutaneous wounds as well as DDR-Sen and cutaneous wounds. (a)** Venn diagrams were prepared as in Fig. 7c. Day 1, 2, 3, 4, 6, and 8 are shown. **(b)** Venn diagrams were prepared as in Fig. 7c except for the fact that top 146 pathways were used for each data set regardless of the z-score significance cutoff line.



Extended Data Fig. 10 | PMD-Sen accelerates wound healing in vitro in a paracrine manner more than DDR-Sen do. (a) Non-senescent recipient cells (young) were co-cultured with PMD-Sen cells (donor) or DDR-Sen cells (donor). (b) Representative images of recipient cells (young) after 0 and 36 hours after

cell-free gap formation are shown. Scale bar, 100  $\mu$ m. This experiment was independently repeated five times with similar results. Related to Fig. 7d. This experiment was independently repeated five times with similar results.

# nature portfolio

Corresponding author(s): Keiko Kono

Last updated by author(s): Jan 19, 2024

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

### **Statistics**

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	$\boxtimes$	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$		A description of all covariates tested
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

### Software and code

Policy information about availability of computer code

Data collection	[Light microscopic observation] Celldiscoverer 7 (Zeiss ZEN2.6), LSM 780 NLO (Zeiss ZEN2.3), AxioObserver7 (Zeiss ZEN 3.1). BZ-9000 (Keyence), Axio Observer z1 (Zeiss ZEN2.3), SP8 (Leica LAS X), A1R (Nikon NIS-Elements ver6.0), DMiL (Leica) equipped with EOS kiss X4 (Cannon).
	[Electron microscopic observation ] JEM-1011J (JEOL), JEM-1400Plus (JEOL) and MI4000L (Hitachi High-Tech)
	[Western blotting] ChemiDoc Touch MP (Bio-Rad)
	[RNA sequencing] Novaseq6000 (Illumina) for 2x 150bp yielding at least 20 M reads per sample
	[Imaging flowcytometry] Amnis Imagestream x Mk II (Millipore) and FCS express (De novo software).
	[Gene expression analysis] QuantStudio 1 (Thermo Fischer Scientific)
Data analysis	[Light microscopic data] Fiji/ImageJ v1.5 or later

[Electron microscopic data] Fiji/ImageJ and AMIRA v5.6 (FEI Visualization Science Group)

[Western blotting] BioRad ImageLab 6.0

[RNA sequencing] Trim\_galore, HISAT2 to the human GRCh38 reference genome, htseq-count, DEseq2, Ingenuity Pathway Analysis (IPA) (Ingenuity Systems)

[Statistical data analysis] GraphPad Prism9, SPSS software version 21.0 (IBM Corp.)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The RNAseq dataset generated and analyzed during the current study is available in the NCBI GEO repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE222400

The rest of the data generated or analyzed during this study are included in this published article (and its supplementary information files).

Externally generated data can be obtained from the following resources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141814

(N14)

http://www.saspatlas.com/

### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

. .

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

🔀 Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size No explicit sample size calculation was performed. We followed community norms and the sample sizes are similar to those reported in previous publications (Ref. 15, 22). Exact sample sizes are indicated in the corresponding figure legends and supplementary figure legends. In Biochemical and spectrometric experiments, each experiment was independently repeated multiple times.

Data exclusions	No data were excluded from the analysis.		
Replication	In principle, at least three independent experiments for each assay were performed to verify the reproducibility of the findings. mRNA-seq was performed with two independent samples. Exact sample sizes / number of independent experiments are indicated in the corresponding figure legends, supplementary figure legends and supplementary data.		
Randomization	All cell culture experiments were randomly assigned to experimental conditions. For microscopic images, the image fields of immunofluorescence and TEM observations, SA- $\beta$ -gal staining were randomly acquired.		
Blinding	The majority of experiments were not blinded because the same investigators performed the experiments and analyzed the data. In addition blinding during data collection was not possible for the majority of these studies because the experimental conditions caused significant		

# Reporting for specific materials, systems and methods

anonymized the data at the time of data collection and only grouped and analyzed the data blindly.

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

phenotypic changes between the groups (untreated vs. treated (senescent), fluorescent marker differences, etc.). For RNA-seq, we

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
	Antibodies	$\boxtimes$	ChIP-seq
	Eukaryotic cell lines		Flow cytometry
$\boxtimes$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
$\boxtimes$	Animals and other organisms		
$\boxtimes$	Clinical data		
$\boxtimes$	Dual use research of concern		
$\boxtimes$	Plants		

### Antibodies

Antibodies used       Rabbit Anti-CHMP4A HPA068473 Sigma-Aldrich (Merck) PRID: AB_268594, 1:1000         Mouse Anti-p53 [IO-1] sc 126 Santa Cruz Biotechnologies PRID: AB_23164, 1:1000       Rabbit Anti-Phospho-p53 (Ser 15) 9284 Cell Signaling Technology PRID: AB_331509, 1:1000         Mouse Anti-p1 Waft/Cigi L(F) Si cc5436 Santa Cruz Biotechnologies PRID: AB_231509, 1:1000       Mouse Anti-p1 (F) Si cc5436 Santa Cruz Biotechnologies PRID: AB_23000         Rabbit Anti-Phospho-p53 (Ser 15) 9284 Cell Signaling Technology PRID: AB_331509, 1:1000       Robert Anti-Phospho-ATM (S1981) AF1555 R&D Systems PRID: AB_208278, 1:200         Rabbit Anti-Phospho-ATM (S1981) AF1555 R&D Systems PRID: AB_202395 1:200       Rabbit Anti-Phospho-ATM (S1981) AF1555 R&D Systems PRID: AB_202395 1:200         Rabbit Anti-Phospho-ATM (S1981) AF1555 R&D Systems PRID: AB_202395 1:200       Mouse Anti-Phospho-H2AX(Ser 139) (SE 1309 Vale 1292 Abcam PRID: AB_206293 1:1000         Mouse Anti-Phospho-H2AX(Ser 139) (SE 1309 Vale 242 Abcam PRID: AB_20668, 1:1000       Mouse Anti-Phospho-H2AX(Ser 139) (SE 1309 Vale 242 Abcam PRID: AB_2078371, 1:1000         Rabbit Anti-Phospho-Ch4I(Ser 139) (SE 1309 Vale 244 Abcam PRID: AB_207804, 1:1000       Rabbit Anti-Phospho-Ch4I(Ser 139) (SE 13303) 2:440 Cell Signaling Technology PRID: AB_20864, 1:1000         Rabbit Anti-Phospho-Ch4I(Ser 139) (SE 1303) 2:442 Cell Signaling Technology PRID: AB_2082071, 1:1000       Rabbit Anti-Phospho-Ch4I(Ser 139) (SE 13303) 2:442 Cell Signaling Technology PRID: AB_2082023, 1:000         Rabbit Anti-Phospho-Ch4I (Ser 139) (SE 13303) 2:442 Cell Signaling Technology PRID: AB_2082023, 1:000       Mouse Anti-Paote Actin antibody		
Mouse Anti-p53 [00-1] sc-126 Santa Cruz Biotechnologies PRID: AB_231464, 1:1000         Rabbit Anti-Phospho-p53 (Ser13) 2284 Cell Signaling Technology PRID: AB_331464, 1:1000         Rabbit Anti-Phospho-p53 (Ser33) 2526 Cell Signaling Technology PRID: AB_231609, 1:1000         Rabbit Anti-P11 Waf1/Cip1 [Fr5] sc-6246 Santa Cruz Biotechnologies PRID: AB_262073, 1:1000         Rabbit Anti-P12 [UR932] Jabit DoS20 Abcam PRID: AB_1068537, 1:5000         Mouse Anti-P16 (JC8] sc-56330 Santa Cruz Biotechnologies PRID: AB_10685268, 1:1000         Rabbit Anti-CNX2A/p16INK44 [EP1473] ab108349 Abcam PRID: AB_10685268, 1:1000         Rabbit Anti-Phospho-ATM (S1981) AF1055 R&D Systems PRID: AB_10685268, 1:1000         Mouse Anti-HX (L2[1141]) Jab78 Abcam PRID: AB_10685268, 1:1000         Mouse Anti-PHospho-H2AX(Ser139) [BW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_209864, 1:1000         Mouse Anti-Phospho-H2AX(Ser139) [BW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_2783871, 1:1000         Rabbit Anti-Hospho-H2AX(Ser139) [BW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_2783871, 1:1000         Rabbit Anti-Hospho-ChK1(Ser45) [Satta Cruz Biotechnologies PRID: AB_2783871, 1:1000         Rabbit Anti-HAXA b11175 Abcam PRID: AB_2321270, 1:1000         Rabbit Anti-PADPHO [D16111] 1574 Cell Signaling Technology PRID: AB_232210, 1:5000         Mouse Anti-Chk1 [IgG [H4] Jakea Huor PUA 8B 432731 Thermo Fisher Scientific PRID: AB_223210, 1:5000         Goat Anti-Rabbit IgG [H4] Jakea Huor PUA AB, 2721321, 1:5000         Goat Anti-Rabbit IgG (H4] Jakea Huor PUA AB, 2721321, 1:5000<	Antibodies used	Rabbit Anti-CHMP4A HPA068473 Sigma-Aldrich (Merck) PRID: AB_2685994, 1:1000
Rabbit Anti-Phospho-p53 (Ser15) 9284 Cell Signaling Technology PRID: AB_331464, 1:1000         Rabbit Anti-Phospho-p53 (Ser33) 2526 Cell Signaling Technology PRID: AB_628073, 1:1000         Rabbit Anti-P21 (PR362) ab109520 Abcam PRID: AB_10860537, 1:5000         Mouse Anti-P1 Tol (CR) Sc-5330 Santa Cruz Biotechnologies PRID: AB_2062935, 1:1000         Rabbit Anti-P1 (D (CR) Sc-5330 Santa Cruz Biotechnologies PRID: AB_2062935, 1:1000         Rabbit Anti-Phospho-ATM (S1981) AP1655 R&D Systems PRID: AB_2062935, 1:200         Rabbit Anti-Phospho-ATM (S1981) AP1655 R&D Systems PRID: AB_2062935, 1:200         Rabbit Anti-HX (Iphospho S1981) [FE19807) ab1229 Abcam PRID: AB_1042027, 1:15000         Mouse Anti-ATM (2C1(1A1)) ab78 Abcam PRID: AB_306059, 1:1000         Mouse Anti-Phistone HZAX (Ser 139) Sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000         Rabbit Anti-Histone HZAX (Ser 139) Sc-517348 Santa Cruz Biotechnology PRID: AB_133122, 1:2000         Rabbit Anti-Fhospho-Chk1(Ser345) (13303) 2348 Cell Signaling Technology PRID: AB_133121, 1:1000         Rabbit Anti-Fhospho-Chk1(Ser345) (13303) 2348 Cell Signaling Technology PRID: AB_133122, 1:2000         Mouse Anti-Phistone HZAX (Ser 139) Sc-517348 Santa Cruz Biotechnology PRID: AB_13224 Sorta         Rabbit Anti-FAP A6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000         Rabbit Anti-FAP A6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000         Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_1052053, 1:500         Mouse Anti-Rabbit Ig6 (H+L) Alexa Fluor PI		Mouse Anti-p53 [DO-1] sc-126 Santa Cruz Biotechnologies PRID: AB 628082, 1:1000
Rabbit Anti-Phospho-p53 (Ser33) 2526 Cell Signaling Technology PRID: AB_331509, 1:1000         Mouse Anti-p21 Waf1/Cip1 (F-5) sc-6246 Santa Cruz Biotechnologies PRID: AB_28073, 1:1000         Rabbit Anti-p21 (EPR362) ab109520 Abcam PRID: AB_10860537, 1:5000         Mouse Anti-p16 (C08) sc-56330 Santa Cruz Biotechnologies PRID: AB_275018, 1:200         Rabbit Anti-CNXIAy/161NK4a (EPR1473) ab108349 Abcam PRID: AB_1064027, 1:1000         Rabbit Anti-CNXIAy/161NK4a (EPR1473) ab108349 Abcam PRID: AB_1064027, 1:1000         Mouse Anti-P11 (D10) ab78 Abcam PRID: AB_306805, 1:1000         Mouse Anti-Phospho-ATM (S1981) [F18907] ab81292 Abcam PRID: AB_1040207, 1:15000         Mouse Anti-Phospho-H2AX(Ser139) JBW301] 05-636 Sigma-Aldrink (Merck) PRID: AB_309864, 1:1000         Mouse Anti-Phospho-H2AX (Ser139) JSC-17348 Santa Cruz Biotechnologies PRID: AB_309864, 1:1000         Rabbit Anti-H2AX (Ser139) JSC-17348 Santa Cruz Biotechnologies PRID: AB_309864, 1:1000         Rabbit Anti-H2AX (Ser139) JSC-17348 Santa Cruz Biotechnologies PRID: AB_31212, 1:2000         Rabbit Anti-H2AX (Ser139) JSC-17348 Santa Cruz Biotechnologies PRID: AB_31212, 1:2000         Rabbit Anti-H2AX (D17A3) 7631 Cell Signaling Technology PRID: AB_1062025, 1:5000         Mouse Anti-Abt JBC (H-1) Alexa Fluor PRID: AB_21570, 1:1000         Rabbit Anti-GAPDH (D16H11) S174 Cell Signaling Technology PRID: AB_10622025, 1:5000         Mouse Anti-Abt JBC (H-1) Alexa Fluor PRID: AB_72139, 1:5000         Coat Anti-Rabbit IG (H-1) Alexa Fluor PRID: AB_772139, 1:5000 <t< td=""><td></td><td>Rabbit Anti-Phospho-p53 (Ser15) 9284 Cell Signaling Technology PRID: AB_331464, 1:1000</td></t<>		Rabbit Anti-Phospho-p53 (Ser15) 9284 Cell Signaling Technology PRID: AB_331464, 1:1000
Mouse Anti-p21 Waf1/Cip1 [F-5] sc-6246 Santa Cruz Biotechnologies PRID: AB_028073, 1:1000         Rabbit Anti-p21 [EPR362] ab 109520 Abcam PRID: AB_01860537, 15:500         Mouse Anti-p21 (EPR362] ab 109520 Abcam PRID: AB_785018, 1:200         Rabbit Anti-COKN2A/p16INK4a [EPR1473] ab 108349 Abcam PRID: AB_785018, 1:1000         Rabbit Anti-COKN2A/p16INK4a [EPR1473] ab 108349 Abcam PRID: AB_02682935 1:200         Rabbit Anti-COKN2A/p16INK4a [EPR1473] ab 108349 Abcam PRID: AB_0262935 1:200         Rabbit Anti-HM (phospho 5181) [EP1890Y] ab 81292 Abcam PRID: AB_026935 1:200         Mouse Anti-ATM [2C1(1A1)] ab78 Abcam PRID: AB_036089, 1:1000         Mouse Anti-Phospho-12XX[Ser139] [W30310 5-6358 (Sigma-Aldrich (Merck) PRID: AB_039864, 1:1000         Mouse Anti-Phospho-12XX [Ser 139] sc-517348 Santa Cruz Biotechnologies PRID: AB_738371, 1:1000         Rabbit Anti-HIStone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_302864, 1:1000         Rabbit Anti-HIStone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_10860771, 1:1000         Rabbit Anti-HIStone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_1086071, 1:1000         Rabbit Anti-FPospho-ChxlX (1017A) 17631 Cell Signaling Technology PRID: AB_1082071, 1:1000         Rabbit Anti-FP A-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000         Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000         Mouse Anti-Atabbit IgG (H4) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_22633280, 1:200         Goat Anti-Rabbit		Rabbit Anti-Phospho-p53 (Ser33) 2526 Cell Signaling Technology PRID: AB 331509, 1:1000
Rabbit Anti-p21 [PR362] abi_0520 Abcam PRID: AB_10860537, 15500         Mouse Anti-p16 (JCB) sc-56303 Sarta Cruz Biotechnologies PRID: AB_785018, 1:200         Rabbit Anti-CKNX2/p161NK43 [PER1473] abi_03249 Abcam PRID: AB_7052015, 1:1000         Rabbit Anti-CKNX2/p161NK43 [PER1473] abi_03249 Abcam PRID: AB_7052015, 1:1000         Rabbit Anti-Phospho-ATM (51981) [PE1890Y] ab81292 Abcam PRID: AB_705000         Mouse Anti-Phospho-H2AX[Ser139] [BW301] 05-635 Sigma-Aldnch (Merck) PRID: AB_309864, 1:1000         Mouse Anti-Phospho-H2AX[Ser139] [BW301] 05-635 Sigma-Aldnch (Merck) PRID: AB_309864, 1:1000         Mouse Anti-Phospho-H2AX[Ser139] [BW301] 05-635 Sigma-Aldnch (Merck) PRID: AB_309864, 1:1000         Rabbit Anti-H5AX abi_1T5 Abcam PRID: AB_297814, 1:2000         Rabbit Anti-H5AX abi_1T5 Abcam PRID: AB_297814, 1:2000         Rabbit Anti-H5AX abi_1T5 Abcam PRID: AB_297814, 1:2000         Rabbit Anti-H5AX (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000         Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_259159, 1:1000         Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_250159, 1:1000         Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_2633280, 1:200         Goat Anti-Rabbit IgG (H4) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200         Goat Anti-Rabbit IgG (H4) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200         Goat Anti-Rabbit IgG (H4) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200 <t< th=""><th></th><th>Mouse Anti-p21 Waf1/Cip1 [F-5] sc-6246 Santa Cruz Biotechnologies PRID: AB 628073, 1:1000</th></t<>		Mouse Anti-p21 Waf1/Cip1 [F-5] sc-6246 Santa Cruz Biotechnologies PRID: AB 628073, 1:1000
Mouse Anti-p16 (IC8) sc-5633 0 santa Cruz Biotechnologies PRID: AB_785018, 1:200Rabbit Anti-CDKN2A/p16INK4a [EPR1473] ab 108349 Abcam PRID: AB_10858268, 1:1000Rabbit Anti-Phospho-1MK (S1981) AF1655 R&D Systems PRID: AB_2062935 1:200Rabbit Anti-ATM (2C1(1A1)) ab78 Abcam PRID: AB_2062935 1:200Mouse Anti-Phospho-H2A.X[Ser139] (BW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_309864, 1:1000Mouse Anti-Phistone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000Rabbit Anti-H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_2783871, 1:1000Rabbit Anti-H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_21212, 1:2000Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_231212, 1:2000Rabbit Anti-Ch4I (DC301) C9355 Sigma-Aldrich (Merck) PRID: AB_235159, 1:1000Rabbit Anti-GPD (D16H11) 5174 Cell Signaling Technology PRID: AB_201652, 1:5000Mouse Anti-Beta Actin antibody (AC-15) ab6276 Abcam PRID: AB_223210, 1:5000Rabbit Anti-GPD (D16H11) 5174 Cell Signaling Technology PRID: AB_2063280, 1:200Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H+2) Alexa Fluor Plus AB_772193, 1:5000Mouse Anti-Rabbit IgG (H+2) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_203923, 1:200Goat Anti-Rabbit IgG (H+2) Alexa Fluor 7076 Cell Signaling Technology PRID: AB_209233, 1:5000Goat Anti-Rabbit IgG (H+2) Alexa Alexa 772193, 1:5000Donkey Anti-Rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_209233, 1:5000Horkey Anti-Rabbit IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_209233, 1:5000Horkey Anti-Rabbit IgG, HRP-linked 7076 Cell		Rabbit Anti-p21 [EPR362] ab109520 Abcam PRID: AB_10860537, 1:5000
Rabbit Anti-CDKN2A/p16lNK4a [EPR1473] ab108349 Abcam PRID: AB_10858268, 1:1000         Rabbit Anti-Phospho-ATM (S1981) AF1655 R8D Systems PRID: AB_1640207, 1:15000         Rabbit Anti-ATM (phospho S1981) [F118097] ab81292 Abcam PRID: AB_1640207, 1:15000         Mouse Anti-ATM [ALC1(1A1]] ab78 Abcam PRID: AB_306089, 1:1000         Mouse Anti-Phospho-H2A X[Ser139] [JBW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_309864, 1:1000         Mouse Anti-Phisone H2AX (Ser139) [JBW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_2783871, 1:1000         Rabbit Anti-Phisone H2AX (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000         Rabbit Anti-Histone H2AX (D17A3) 7631 Cell Signaling Technology PRID: AB_31212, 1:2000         Mouse Anti-Hospho-Chk1(Ser345) [J330] 2348 Cell Signaling Technology PRID: AB_31212, 1:2000         Mouse Anti-Chk1 [DC5310] C9358 Sigma-Aldrich (Merck) PRID: AB_232121, 1:2000         Mouse Anti-CAPPH (D111) 5174 Cell Signaling Technology PRID: AB_31212, 1:2000         Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_2223210, 1:5000         Goat Anti-Rabbit IgG (H+1) Alexa Fluor 674 A55055 Thermo Fisher Scientific PRID: AB_2232310, 1:200         Goat Anti-Rabbit IgG (H+1) Alexa Fluor 674 A55055 Thermo Fisher Scientific PRID: AB_209233, 1:2500         Sheep Anti-mouse IRP IgG NA9310 Cytiva PRID: AB_772191, 1:5000         Goat Anti-Rabbit IgG (H+0) Alexa Fluor 674 A55055 Thermo Fisher Scientific PRID: AB_209233, 1:2500         Sheep Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000         Ho		Mouse Anti-p16 (JC8) sc-56330 Santa Cruz Biotechnologies PRID: AB 785018, 1:200
ValidationValidationValidationValidationValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunoffluorescence staining,ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by and overavoression of GFP-tagged protein by Western blotting / immunoffluorescence staining,ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of		Rabbit Anti-CDKN2A/p16INK4a [EPR1473] ab108349 Abcam PRID: AB 10858268, 1:1000
Rabbit Anti-ATM (phospho \$1981) [EP1890Y] ab81292 Abcam PRID: AB_1640207, 1:15000 Mouse Anti-ATM [2C1(1A1)] ab78 Abcam PRID: AB_30698, 1:1000 Mouse Anti-PAX, Variab J [JBX930] 05-636 Sigma-Aldrich (Merck) PRID: AB_309864, 1:1000 Mouse Anti-P-Histone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000 Rabbit Anti-H2A.X ab11175 Abcam PRID: AB_27814, 1:2000 Rabbit Anti-Histone H2A.X (Ser 137) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000 Rabbit Anti-Phospho-Chk1(Ser345) [13303] 2348 Cell Signaling Technology PRID: AB_331212, 1:2000 Mouse Anti-CFP A-6455 Thermor Fisher Scientific PRID: AB_259159, 1:1000 Rabbit Anti-GPA A-6455 Thermor Fisher Scientific PRID: AB_22310, 1:2000 Rabbit Anti-GPA A-6455 Thermor Fisher Scientific PRID: AB_223210, 1:5000 Mouse Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_123210, 1:5000 Goat Anti-Rabbit IgG (H1) Alexa Fluor Plus 48A 32731 Thermo Fisher Scientific PRID: AB_263280, 1:200 Goat Anti-Rabbit IgG (H2) Alexa Fluor Plus A8A 32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (NA9310 Cytiva PRID: AB_727193, 1:5000 Donkey Anti-Rabbit IgG NA9310 Cytiva PRID: AB_727193, 1:5000 Goat Anti-Rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_209233, 1:5000 Horse Anti-mouse IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_209233, 1:5000 Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000 hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_22861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-taged protein by Western blotting / immunofluorescene staining, CHMP4A (Sigma HPA068473) (Hch ttps://www.sigmaaldi		Rabbit Anti-Phospho-ATM (S1981) AF1655 R&D Systems PRID: AB_2062935 1:200
Mouse Anti-ATM [2C1(1A1)] ab78 Abcam PRID: AB_306089, 1:1000Mouse Anti-Phisopho-H2AX (Ser139) (JBW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_2783871, 1:1000Mouse Anti-Phisopho H2AX (Ser 139) sc.517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000Rabbit Anti-H2AX ab11175 Abcam PRID: AB_297814, 1:2000Rabbit Anti-Histone H2AX (Ser 139) sc.517348 Santa Cruz Biotechnology PRID: AB_10860771, 1:1000Rabbit Anti-Histone H2AX (Ser 139) sc.517348 Cell Signaling Technology PRID: AB_10860771, 1:1000Rabbit Anti-Histone H2AX (D17A3) 7631 Cell Signaling Technology PRID: AB_31212, 1:2000Mouse Anti-Chk1 [DC3310] C9385 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_20205, 1:5000Mouse Anti-Adbit IgG (H+1) S174 Cell Signaling Technology PRID: AB_223210, 1:5000Mouse Anti-Habbit IgG (H+1) S174 Cell Signaling Technology PRID: AB_223210, 1:200Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H+2) Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit IgG NA9340 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-Actin #112004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining, <th></th> <th>Rabbit Anti-ATM (phospho S1981) [EP1890Y] ab81292 Abcam PRID: AB_1640207, 1:15000</th>		Rabbit Anti-ATM (phospho S1981) [EP1890Y] ab81292 Abcam PRID: AB_1640207, 1:15000
Mouse Anti-Phospho-H2A.X (Ser 139) [JBW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_309864, 1:1000 Mouse Anti-P-Histone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000 Rabbit Anti-H2A.X ab1175 Abcam PRID: AB_297814, 1:2000 Rabbit Anti-Hospho-Chk1(Ser345) [13303] 2348 Cell Signaling Technology PRID: AB_10860771, 1:1000 Rabbit Anti-Phospho-Chk1(Ser345) [13303] 2348 Cell Signaling Technology PRID: AB_331212, 1:2000 Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRD: AB_259159, 1:1000 Rabbit Anti-GPA-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000 Rabbit Anti-GPA P.6455 Thermo Fisher Scientific PRID: AB_2232120, 1:5000 Mouse Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000 Mouse Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (H) Alexa Fluor Flus 482 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (H) Alexa Fluor Flus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (H) Alexa Fluor Flus 482 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (H) Alexa Fluor C47 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250 Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000 Goat Anti-Rabbit IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_2099233, 1:5000 Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000 hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,ValidationThe validatio		Mouse Anti-ATM [2C1(1A1)] ab78 Abcam PRID: AB_306089, 1:1000
Mouse Anti-p-Histone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000 Rabbit Anti-H2A.X ab11175 Abcam PRID: AB_2797814, 1:2000 Rabbit Anti-H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000 Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_132121, 1:2000 Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000 Rabbit Anti-GPP A-6455 Thermo Fisher Scientific PRID: AB_259159, 1:1000 Rabbit Anti-GPP A-6455 Thermo Fisher Scientific PRID: AB_259159, 1:1000 Rabbit Anti-GPP A-6455 Thermo Fisher Scientific PRID: AB_22025, 1:5000 Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_2223210, 1:5000 Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_263280, 1:200 Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_263280, 1:200 Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_263280, 1:200 Goat Anti-Rabbit IgG (H+1) Alexa Fluor Plus A88_771193, 1:5000 Donkey Anti-Rabbit IgG (H+1) Alexa Fluor Plus AB_772193, 1:5000 Donkey Anti-Rabbit IgG (HPI) File A07310 Cytiva PRID: AB_772193, 1:5000 Donkey Anti-Rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000 Horse Anti-mouse IRP IgG NA9340 Cytiva PRID: AB_72193, 1:5000 Goat Anti-Rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_30924, 1:5000 Horse Anti-mouse IGG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000 hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immuno		Mouse Anti-Phospho-H2A.X(Ser139) [JBW301] 05-636 Sigma-Aldrich (Merck) PRID: AB_309864, 1:1000
Rabbit Anti-H2A.X ab11175 Abcam PRID: AB_297814, 1:2000Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_331212, 1:2000Mouse Anti-Chk1 [DC3310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_1082025, 1:5000Mouse Anti-Chk1 [DC310] C9358 Sigma-Aldrich (Merck) PRID: AB_2223210, 1:5000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_1022025, 1:5000Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000Goat Anti-Rabbit IgG (H+L) Jkaz Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG, HAP-linked 7074 Cell Signaling Technology PRID: AB_209233, 1:5000Donkey Anti-Rabit IgG, NA9340 Cytiva PRID: AB_772193, 1:5000Goat Anti-rabit IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000hrad thir-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/IP/ja/product/sigma/hpa068473 ) This antibody was further validated using signAs and overewrression of GFP-tag		Mouse Anti-p-Histone H2A.X (Ser 139) sc-517348 Santa Cruz Biotechnologies PRID: AB_2783871, 1:1000
Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000Rabbit Anti-Phospho-Chk1(Ser345) [133D3] 2348 Cell Signaling Technology PRID: AB_331212, 1:2000Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000Rabbit Anti-GPA-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000Mouse Anti-Aabbit Ig6 (H+L) Alexa Fluor PILs AB_221370, 1:000Goat Anti-Rabbit Ig6 (H+L) Alexa Fluor PILs 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit Ig6 (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit Ig6 (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP Ig6 NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit Ig6, HRP-linked 7074 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse Ig6, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse Ig6, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (HC https://www.sigmaldrich.com/JP/ja/product/sigma/hpa068473 ) This authody was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent <th></th> <th>Rabbit Anti-H2A.X ab11175 Abcam PRID: AB_297814, 1:2000</th>		Rabbit Anti-H2A.X ab11175 Abcam PRID: AB_297814, 1:2000
Rabbit Anti-Phospho-Chk1(Ser345) [133D3] 2348 Cell Signaling Technology PRID: AB_331212, 1:2000Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit HRP IgG NA9310 Cytiva PRID: AB_772191, 1:5000Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (He https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) Tis antihodv was further validated using siBNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent		Rabbit Anti-Histone H2A.X (D17A3) 7631 Cell Signaling Technology PRID: AB_10860771, 1:1000
Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000Mouse Anti-bata Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473)(HC https://www.sigmaldrich.com/JP/ja/product/sigma/hpa068473 )This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Rabbit Anti-Phospho-Chk1(Ser345) [133D3] 2348 Cell Signaling Technology PRID: AB_331212, 1:2000
Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H+L) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:200ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.ccm/JP/ja/product/sigma/hpa068473 ) Tie antibody was further validated using siBNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Mouse Anti-Chk1 [DCS310] C9358 Sigma-Aldrich (Merck) PRID: AB_259159, 1:1000
Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000 Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000 Goat Anti-Rabbit IgG (H+L) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2633280, 1:200 Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250 Sheep Anti-mouse HRP IgG NA9340 Cytiva PRID: AB_772193, 1:5000 Donkey Anti-Rabit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000 Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_30924, 1:5000 hrAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining, CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/IP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Rabbit Anti-GFP A-6455 Thermo Fisher Scientific PRID: AB_221570, 1:1000
Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent		Rabbit Anti-GAPDH (D16H11) 5174 Cell Signaling Technology PRID: AB_10622025, 1:5000
Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000Horse Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/IP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Mouse Anti-beta Actin antibody [AC-15] ab6276 Abcam PRID: AB_2223210, 1:5000
Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000horse Anti-abbit IgG (H) Alexa PRID: AB_2861334, 1:2000ValidationThe validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,CHMP4A (Sigma HPA068473) (HC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Goat Anti-Rabbit IgG (H+L) Alexa Fluor Plus 488 A32731 Thermo Fisher Scientific PRID: AB_2633280, 1:200
Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000         Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000         Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000         Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000         hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000         Validation         The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)       (HC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Goat Anti-Rabbit IgG (H) Alexa Fluor 647 A55055 Thermo Fisher Scientific PRID: AB_2921063, 1:250
Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000         Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000         Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000         hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000         Validation         The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)       (HC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Sheep Anti-mouse HRP IgG NA9310 Cytiva PRID: AB_772193, 1:5000
Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000         Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000         hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000         Validation         The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)         (HC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Donkey Anti-Rabit HRP IgG NA9340 Cytiva PRID: AB_772191, 1:5000
Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000         hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000         Validation         The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)         (IHC https://www.sigmaaldrich.com/IP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Goat Anti-rabbit IgG, HRP-linked 7074 Cell Signaling Technology PRID: AB_2099233, 1:5000
hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000         Validation         The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)         (IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		Horse Anti-mouse IgG, HRP-linked 7076 Cell Signaling Technology PRID: AB_330924, 1:5000
Validation       The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,         CHMP4A (Sigma HPA068473)       (HC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )         This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent		hFAB Rhodamine Anti-Actin #12004164 Bio-Rad PRID: AB_2861334, 1:2000
<ul> <li>Validation</li> <li>The validation of the antibodies was performed by the indicated manufacturers and supported by the publication indicated on the manufacturer's website. Some of the antibodies were additionally validated by us using the corresponding siRNAs or overexpression of GFP-tagged protein by Western blotting / immunofluorescence staining,</li> <li>CHMP4A (Sigma HPA068473)</li> <li>(IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 )</li> <li>This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent</li> </ul>	Validation	The validation of the aptihodios was performed by the indicated manufacturers and supported by the publication indicated on the
of GFP-tagged protein by Western blotting / immunofluorescence staining, CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent	Validation	menufacture of the antibodies was performed by the indicated manufacture is and supported by the publication indicated on the manufacture of supported by the publication indicated on the
CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This anti-body was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent		of GED-taged protein by Wastern blotting / immunofluorescent adjust adjust using the corresponding sinvers of overexpression
CHMP4A (Sigma HPA068473) (IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This antibody was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent		or or - tagged protein by western blotting / initiationalorescence stalling,
(IHC https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa068473 ) This anti-hody was further validated using siRNAs and overexpression of GEP-tagged protein by Western blotting and fluorescent		CHMP44 (Sigma HP4068473)
This antibody was further validated using siRNAs and overwaression of GEP-tagged protein by Western blotting and fluorescent		(IHC https://www.sigmaaldrich.com/IP/ia/product/sigma/hpa068473.)
This difficient was fulled wind the value of the sine of the second of t		This antibody was further validated using siRNAs and overexpression of GFP-tagged protein by Western blotting and fluorescent

immunostaining
p53 [DO-1] (Santa Cruz sc-126) (WB, IP, IF, IHC, FCM https://www.scbt.com/p/p53-antibody-do-1 ) This antibody was further validated using siRNAs by Western blotting.
Phospho-p53 (Ser15) (CST 9284) (WB, IP https://www.cellsignal.jp/products/primary-antibodies/phospho-p53-ser15-antibody/9284 )
Phospho-p53 (Ser33) (CST 2526) ( WB, IHC https://www.cellsignal.jp/products/primary-antibodies/phospho-p53-ser33-antibody/2526 )
p21 Waf1/Cip1 [F-5] (Santa Cruz sc-6246) ( WB, IP, IF, IHC,FCM https://www.scbt.com/p/p21-antibody-f-5 ) This antibody was further validated by overexpression of GFP-tagged protein by Western blotting.
p21 [EPR362] (Abcam ab109520) ( WB, IF, IHC, FCM https://www.abcam.com/en-mx/products/primary-antibodies/p21-antibody-epr362-ab109520 ) This antibody was further validated by overexpression of GFP-tagged protein by Western blotting.
p16 (JC8) (Santa Cruz sc-56330) (WB, IP, IF, IHC, ELISA https://www.scbt.com/p/p16-antibody-jc8 )
CDKN2A/p16INK4a [EPR1473] (Abcam ab108349) (WB, IP, IHC https://www.abcam.com/en-ee/products/primary-antibodies/cdkn2a-p16ink4a-antibody-epr1473-c-terminal-
ab108349 ) We further validated this antibody by overexpressing GFP-tagged protein by Western blotting and confirmed that this antibody reacts only with p16 and not with p15.
Phospho-ATM (S1981) (R&D AF1655) (WB https://www.rndsystems.com/products/human-mouse-rat-phospho-atm-s1981-antibody_af1655 )
ATM (phospho S1981) [EP1890Y] (Abcam ab81292) ( WB, IP, IHC, FCM https://www.abcam.com/en-at/products/primary-antibodies/atm-phospho-s1981-antibody-ep1890y-ab81292 )
ATM [2C1(1A1)] (Abcam Ab78) (WB, IP, IHC, FCM https://www.abcam.com/en-za/products/primary-antibodies/atm-antibody-2c1-1a1-bsa-and-azide-free-ab78 )
Phospho-H2A.X(Ser139) [JBW301] (Sigma 05-636) (WB, IP, IF, IHC https://www.emdmillipore.com/US/en/product/Anti-phospho-Histone-H2A.X-Ser139-Antibody-clone- JBW301,MM_NF-05-636?bd=1 )
p-Histone H2A.X (Ser 139) (Santa Cruz sc-517348) (WB, IF https://www.scbt.com/p/p-histone-h2a-x-antibody-ser-139 )
H2A.X (Abcam ab11175) (WB, IHC https://www.abcam.com/products/primary-antibodies/histone-h2ax-antibody-ab11175.html )
Histone H2A.X (D17A3) (CST 7631) (WB, IP, IF, IHC, FCM https://www.cellsignal.jp/products/primary-antibodies/histone-h2a-x-d17a3-xp-rabbit-mab/7631)
Phospho-Chk1(Ser345) [133D3] (CST 2348) (WB, IF, FCM https://www.cellsignal.jp/products/primary-antibodies/phospho-chk1-ser345-133d3-rabbit-mab/2348 )
Chk1 [DCS310] (Sigma C9358) (WB, IP, IHC https://www.sigmaaldrich.com/US/en/product/sigma/c9358 )
GFP (Thermo Fisher A-6455) (WB, IP, IF, IHC, FCM, ELSA https://www.thermofisher.com/antibody/product/GFP-Antibody-Polyclonal/A-6455 )
GAPDH (D16H11) (CST 5174) (WB, IF, IHC https://www.cellsignal.com/products/primary-antibodies/gapdh-d16h11-xp-rabbit-mab/5174?language=en)
beta Actin [AC-15] (Abcam ab6276) (WB, IF https://www.abcam.com/en-at/products/primary-antibodies/beta-actin-antibody-ac-15-ab6276 )
Rabbit IgG (H+L) Alexa Fluor Plus 488 (Thermo Fisher A32731) (WB, IF https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody- Polyclonal/A32731 )
Rabbit IgG (H) Alexa Fluor 647 (Thermo Fisher A55055) (WB, IF, FCM https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-Heavy-chain-Secondary-Antibody- Recombinant-Polyclonal/A55055 )

Mouse HRP IgG (Cytiva NA9310) (WB https://www.cytivalifesciences.com/en/us/shop/protein-analysis/blotting-and-detection/blotting-standards-and-reagents/ amersham-ecl-hrp-conjugated-antibodies-p-06260)

Rabit HRP IgG (Cytiva NA9340) (WB https://www.cytivalifesciences.com/en/us/shop/protein-analysis/blotting-and-detection/blotting-standards-and-reagents/ amersham-ecl-hrp-conjugated-antibodies-p-06260)

Rabbit IgG, HRP-linked (CST 7074) (WB https://www.cellsignal.com/products/secondary-antibodies/anti-rabbit-igg-hrp-linked-antibody/7074?country=USA )

Mouse IgG, HRP-linked (CST 7076) (WB https://www.cellsignal.com/products/secondary-antibodies/anti-mouse-igg-hrp-linked-antibody/7076)

Rhodamine Anti-Actin (Bio-Rad #12004164) (WB https://www.bio-rad.com/en-jp/sku/12004164-hfab-rhodamine-anti-actin-primary-antibody-40-ul?ID=12004164)

### Eukaryotic cell lines

Policy information about <u>cell lines</u>	s and Sex and Gender in Research
Cell line source(s)	HeLa cell line, endocervical adenocarcinoma, female, from RIKEN BRC Cat# RCB0007, RRID:CVCL_0030 WI-38 cells, fibroblast, female, PDL36.6 from RIKEN BRC Cat# RCB0702, RRID:CVCL_0579 WI-38 cells, fibroblast, female, PDL32.2 from JCRB cell bank Cat# IFO50075, RRID:CVCL_0579 BJ cells, fibroblast, male, PDL24.0 from ATCC, Cat# CRL-2522, RRID:CVCL_3653 HCA2, fibroblast we previously described in DOI: 10.1073/pnas.92.10.4352, male, PDL16.0. This cell is not commercially available.
Authentication	HeLa cell line (RIKEN: morphology, PCR assays with species-specific primers, Karyotyping), WI-38 cells (RIKEN: morphology, STR profiling, Isozyme analysis for the Identification of species, Karyotyping), WI-38 cells (JCRB: Isozyme analysis for the Identification of species) and BJ cells (ATCC: STR profiling) were authenticated by the supplier. HCA2 cells were authenticated by the authors in DOI: 10.1073/pnas.92.10.4352, and no further authentication was performed in the laboratory.
Mycoplasma contamination	All cells have been confirmed mycoplasma negative by the distributor. In addition, all cells are periodically stained by Hoechst 33342 to confirm that they are mycoplasma negative.
Commonly misidentified lines (See <u>ICLAC</u> register)	No misidentified lines were used in this study.

#### **Plants**

Seed stocks	Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.
Novel plant genotypes	Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor
Authentication	was applied. Describe any authentication procedures for each-seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.

### Flow Cytometry

#### Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

🔀 The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation

WI-38 cells cultured in DAPI containing media with or without SDS. Cells were fixed with 4% PFA before resuspended in flow cytometry buffer.

Instrument

ImageStream x MKII (Millipore)

Software	FCS express (De novo software)	
Cell population abundance	Samples were not sorted in this study	
Gating strategy	We did not gate any data.	
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.		